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Hereditary nonpolyposis colorectal cancer (HNPCC) is an inherited predisposition to early 
onset colorectal and endometrial cancer, caused by mutations in DNA mismatch repair 
genes. It is the most common form of hereditary colorectal cancer (CRC) and has a 
worldwide prevalence of 1 in 3 000 persons. As the mortality and morbidity related to 
HNPCC is decreased through surveillance for CRC. it can be .beneficial for an individual to 
know if they are likely to develop an HNPCC-related cancer. Once a disease-causing 
mutation has been identified in an affected individual. predictive testing can be offered to 
first-degree relatives to refine their risk. 
The purpose of this study was to explore the level of understanding of the predictive test 
result and subsequent impact of testing for a predisposition to HNPCC. Using a qualitative 
research design, in-depth interviews were conducted with ten individuals (all mutation-
positive and asymptomatic for CRC) subsequent to the disclosure of their predictive test 
result. The use of personal interviews could construct rich descriptions of the circumstances 
faced by these individuals, following their predictive testing for HNPCC. 
Study results showed a good level of knowledge and understanding related to HNPCC. The 
results also illustrated that knowledge derived from personal experience often took 
precedence over the information received during counselling. This was especially evident in 
relation to the perceived risk for CRC. Furthermore. predictive testing for HNPCC did not 
seem to induce any significant psychological problems for the participants. In addition, the 
emerging data is promising with regard to the health-related behaviour. 
Limited literature is available internationally and non-existent in South Africa, on the 
individual's understanding and impact of predictive testing, for HNPCC. This study provides 
a useful framework for further research, together with potential implications for genetic 
counselling. Recommendations, to improve the counselling process and genetic services in 
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Adenoma: A benign tumour that develops from epithelial tissue. 
Autosomal dominant inheritance: The expression of a gene in the heterozygous state, 
located on an autosome. 
ColonoKoPY: A medical procedure, which permits the visual examination of the entire 
colon, using an illuminated flexible endoscope. 
Colectomy: Surgical removal of part or ,all of the colon. 
DNA: The genetic material of a cell, which allows for the transmission of genetic 
information from one generation to the next. 
Gene: A sequence of DNA that codes for a particular protein. 
Germline mutation: A heritable mutation in the lineage of germ cells. These mutations are 
transmitted to offspring. 
HNPCC: An autosomal dominant cancer syndrome characterised by early-onset colorectal 
cancer with an absence or limited number of colonic polyps, usually occurring in the 
proximal colon. There is also a predisposition to other extracolonic cancers. 
Deorectal anastomosis: Surgery involving the removal of the colon, which leaves the 
rectum intact by attaching the ileum to the rectum. 
Mutation: An alteration in the DNA sequence or chromosome structure, damaging the 












Polyp: A mucousal protuberance into the lumen of the colon. 
Predictive testing: A form of genetic testing which is capable of identifying the presence of 
a mutation in a gene prior to the individual developing any symptoms of the disease. The 
detection of the genetic mutation does not necessarily mean the individual will definitely 
develop the disorder. 
Predisposition: Having a greater than average risk of developing a disease as a result of an 
inherited gene mutation. 
Prophylactic surgery: Surgery performed before a particular phenotype manifests itself in 
the individual. 
Sigmoidoscopy: A medical procedure involving the examination of the rectum and the 
lower portion of the colon (sigmoid colon) through an illuminated sigmoidoscope. 
Tumour: An abnormal mass of tissue resulting from excessive cell division. This may be 
benign (non-cancerous) or malignant (cancerous). 














In this dissertation the following terms are defined as: 
"Asymptomatic" refers to the fact that the individuals in this study have no clinical history 
of colorectal cancer 
"Cancer" refers specifically to that of an HNPCC-related cancer, unless stated otherwise 
"Estimated risk" refers to the lifetime risk for colorectal cancer, expressed as a percentage 
"Genetic testing" refers to predictive genetic testing, unless specified otherwise 
"Mutation-positive" refers to individuals who have received their predictive test result, 
which confirms that they carry the gene mutation predisposing to HNPCC 
"Perceived risk" refers to the individual's personal perception of the risk of developing 
colorectalcancer 





















CHAPTER I: INTRODUCTION 
CHAPTER ONE 
1.1 INTRODUCTION 
One of the most commonly occurring cancers in western countries is colorectal cancer 
(CRC), with a worldwide incidence exceeding one million cases and mortality of over half a 
million (Hampel et al 2005). In South Africa (SA), CRC is the third most common cancer in 
females and fourth in males. According to the Cancer Association of South Africa 
(CANSA), the risk of developing CRC amongst South Africans is 1 in 91 for males and 1 in 
134 for females. 
Genetic alterations contribute to the development of all colorectal malignancies. In the 
majority of these cases the mutations are acquired and CRC occurs sporadically. usually in 
individuals over the age of 50 years, without the presence of a family history (Schulmann et 
al 2002). In approximately 5-15% of patients, a family history is apparent, and a subset of 
these patients carry germ line mutations that play a central role in the aetiology of their 
disease (Abdel-Rahman et a1 2006; Hampel et al 2005). Inherited forms of cancer include a 
group of distinct syndromes, in which germ line mutations result in an autosomal dominant 
disorder with a predilection for CRC (Strate and Syngal 2005). These include familial 
adenomatous polyposis (F AP) and hereditary nonpolyposis colorectal cancer (HNPCC), 
amongst others. HNPCC is the most common form of hereditary CRC, and will form the 
focus of this review (Devlin et aI2005). 
HNPCC is an autosomal dominant inherited cancer syndrome, predisposing individuals who 
carry the mutated gene, to a high risk (80-85%) of colorectal and endometrial cancer. This 
syndrome is caused by germline mutations in DNA mismatch-repair genes (Schulmann et al 
2002). The international prevalence ofHNPCC is 1 in 3000 persons (Young 2001). To date, 
despite considerable effort, the incidence or prevalence statistics for HNPCC. in SA, have 
not been published. 
The diagnosis of an inherited form of CRC in a family raises many questions for family 
members relating to their own health status. First-degree relatives of an individual with 
HNPCC have a 50% risk of inheriting the mutation and are advised to follow increased 











CHAPTER 1: INTRODUCTION 
Town initiated research into HNPCC in 1988. and services providing predictive genetic 
testing have been available since 1994 (The genetic testing protocol and policy guidelines 
are included in Appendix V. and further details are available from the Division of Human 
Genetics' website at http://www.uct.ac.zaldePts/seneticsl). Predictive testing can identify the 
underlying mutations that result in the predisposition to HNPCC. and mutation-carrying 
individuals can be advised to engage in appropriate risk-management strategies. For 
individuals who are tested and have not inherited the mutation, the intensive medical 
surveillance and anxiety about the increased risk for developing CRC is removed (Claes et al 
2004). 
Predictive testing is offered to at-risk, asymptomatic family members in whom the familial 
mutation in an affected relative has been identified. Ail candidates for the predictive test 
receive non-directive genetic counselling prior to the test. During this session, information 
concerning HNPCC and its heritability. cancer risks, predictive testing and options for 
prevention and early detection are discussed. The pre-test counselling provides information 
to facilitate an informed autonomous decision regarding the uptake of genetic testing. If 
testing is requested the result is given in a post-test counselling session, during which issues 
relating to the interpretation. screening recommendations based on the test result, and the 
psychological and social impact on the individual and family are addressed. Following the 
disclosure of the test result. psychological and medical follow-up is offered appropriate to 
the mutation status of the individual. 
Genetic testing for cancer predisposition can have a profound effect on the individual and 
family. both practically and emotionally. Insight into the individual's understanding of the 
predictive test in HNPCC is needed because of its potential impact on distress and health-
related behaviour (Claes et al 2005). A limited number of international studies have reported 
on the psychosocial impact of genetic counselling and testing (Gritz et a12005; Meiser et al 
2004; Keller et al 2002), but to date. no research in SA has been published on this aspect in 
terms of the individual's understanding and impact of their predictive test result. There is 
thus a need to address the local situation given the possible differences between this country 











CHAPTER 1: INTRODUCTION 
1.2 AIM 
The aim of this study was to investigate the: 
• level of understanding of a genetic predisposition to cancer following predictive 
testing for HNPCC in a cohort of asymptomatic mutation-positive individuals; 
• investigate the motivations for predictive testing; and the 
• subsequent impact on the individual. 
1.3 OBJECTIVES: 
• To establish the sociodemographics ofthe study population; 
• To investigate the level of understanding of the predictive genetic test; 
• To explore the individual's perceived risk of developing CRC; and 
• To investigate the impact of genetic testing for HNPCC on the individual 
1.4 ORGANISATION OF THE STUDY 
Chapter Two presents an overview of current literature on HNPCC. 
Chapter Three discusses the methodology design and outlines the entire research process. 
The steps involved in selecting participants are described and the validity and 
reliability/trustworthiness of the measurement instrument is discussed. A description of the 
data collection and analysis is provided while addressing ethical principles. 
Chapter Four presents and discusses the results of the research study. 
Chapter Five summarizes the main findings in the conclusion ofthe study. 





















CHAPTER 2: LITERATURE REVIEW 
CHAPTER TWO 
2.1 INTRODUCTION 
The literature review will present an overview of HNPCC, including clinical and molecular 
diagnosis, management and surveillance recommendations. Cancer in general has negative 
connotations and the psychosocial impact of genetic counselling and predictive testing for 
individuals at risk for HNPCC will also be reviewed. Literature searches were performed 
using terms such as "genetic testing," "predictive testing," "genetic counselling and testing," 
"genetic susceptibility testing" and "testing for cancer susceptibility" on Pubmed, 
ScienceDirect, Ebscohost and CancerLit for research on genetic testing for familial cancers, 
with specific reference to HNPCC. No published studies were found on the experience of 
genetic testing in terms of the psychological impact and understanding of the predictive test 
result for HNPCC in SA. 
2.2 HEREDITARY NONPOLYPOSIS COLORECTAL CANCER (HNPCC) 
2.2.1 Characteristics of HNPCC 
HNPCC, also termed Lynch syndrome, was originally called cancer family syndrome. The 
history ofHNPCC dates back to 1913 when Aldred Warthin described his observations ofa 
cancer prone family (Warthin 1913). It was first delineated as a hereditary cancer syndrome 
in 1966 following the identification of two further families by Henry Lynch (Anwar et al 
2000; Lynch and Krush 1971). HNPCC is the most common form of hereditary colorectal 
cancer accounting for estimates as high as 5% of all CRCs, although population-based 
studies reflect estimates closer to that of 1-2% (Young 2001; Salovaara et al 2000; Lynch 
and Smyrk 1996; Stephenson et al 1991). HNPCC is an inherited autosomal dominant 
condition reSUlting from mutations in one of several DNA mismatch repair (MMR) genes. A 
mutation in the MMR gene leads to the accumulation of cell mutations, which greatly 
increase the likelihood of malignant transformation and cancer (Naussbaum et al 2004; Korf 
2000). These mutations confer a lifetime risk of 80-85% of developing CRC and an elevated 
risk for several other extracolonic cancers, of which endometrial cancer is the most common 
(Lynch and de la Chapelle 2003). Offspring and first-degree relatives of patients with 
HNPCC have a 50% chance of inheriting the gene defect. At-risk individuals are advised to 
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long. once started (Vasen et aI2005). Through regular colorectal surveillance, polyps can be 
removed before they progress to cancer or the cancer can be detected at an early stage when 
still treatable (Yu et a12003; Lynch et aI1996). 
2.2.2 Diagnostic criteria 
Prior to the identification of causative genes in the 1990's, the diagnosis of HNPCC was 
exclusively based on the evaluation of clinical fmdings together with pedigree analysis 
(Lynch et al 1998). The diagnosis is considered in young patients (mean age 44 years) with 
CRC, patients with multiple primary colonic cancers, or when a family clustering of either 
colorectal or endometrial cancer is observed (Lynch and de la ChapeUe 2003). The features 
which typify HNPCC are provided in Figure 2.1. 
Familial clustering of colorectal and/or endometrial cancer 
Associated cancers· 
Development of cancer at an early age 
Development of multiple cancers 
Features of colorectal cancer: 
IJ predilection for proximal colon 
IJ improved survival as compared to sporadic cancer 
[J multiple colorectal cancers 
IJ increased proportion of mucinous tumours, poorly differentiated tumours, and 
tumours with marked lymphocytic infiltration and lymphoid aggregation at the 
tumour margin 
Features of colorectal adenoma: 
IJ the numbers vary from one to a few 
IJ increased proportion of adenomas with a villous growth pattern 
IJ a high degree of dysplasia 
IJ probably rapid progression from adenoma to carcinoma 
High frequency of microsatellite instability 
Immunohistochemistry: loss of gene protein expression 
Germ-line mutation in MMR genes 
• ovary, stomach, small bowel, hepatobiliary tract, ureter/renal pelvis and brain 
Figure 1.1 ICG - HNPCC Definition of Hereditary Nonpolyposis Colorectal Cancer (Vasen 
et aI1999). 
2.2.3 Clinical presentation 
HNPCC is a cancer predisposition syndrome without any clear clinical signs preceding 
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diagnosing HNPCC arise due to the lack of a characteristic phenotype and several attempts 
have been made to define the clinical criteria for diagnosis. Diagnostic criteria (Table 2.1) 
for HNPCC were initiated by the International Collaborative Group on HNPCC (ICG-
HNPCC) in 1990 and later revised to include extracolonic cancers (Vasen et al 1999; Vasen 
et aI1991). Essentially, criteria have been developed to identifY patients, who are most likely 
to benefit from genetic testing, which is central to making an accurate clinical diagnosis. 
TABLE 2.1: Diagnostic criteria for HNPCC as defined by the International Collaborative 
Group on HNPCC (Adapted from Vasen 1999; inSiGHT Database). 
Classic criteria (Amsterdam I-Vuen et aI1991) 
• At least three relatives affected with CRC; 
• One ofthe affected should be a first degree relative ofthe other two affected individuals; 
• At least one of the CRC cases should be identified before the age of 50 years; 
• F AP should be excluded; and 
• Tumours should be verified by pathology 
(all criteria need to be present) 
Revised criteria (Amsterdam ll-V uen et all999) 
• At least thr,ee affected relatives should be affected with HNPCC related cancer, 
including CRC, cancer of the endometrium, small bowel, ureter, or renal pelvis; 
• One of the affected individuals should be a first-degree relative of the other two affected 
individuals; 
• At least two successive generations should include affected family members; 
• At least one of the CRC cases should be diagnosed before the age of 50 years; 
• F AP should be excluded; and 
• Tumours should be verified by pathology 
(Ail the preceding criteria should be included) 
2.2.4 Moiecultu'.Ktmetics 
HNPCC is caused by mutations in MMR genes. The MMR genes encode for a family of 
proteins that recognise, excise and correct mismatches occurring during DNA replication 
(Yu et al 2003). The MMR gene can remain functional when one allele is compromised, 
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remaining allele, the MMR system is less capable of repairing DNA mismatch errors (Anwar 
et al 2000). A mutation in the MMR gene leads to the accumulation of cell mutations, which 
gather errors at a rate of 30-1000 times that of a nonnal cell, increasing the likelihood of 
malignant transfonnation and cancer (Yu et al 2003; Naussbaum et al 2004; Korf 2000; 
Lynch et al 1998). 
Although seven genes have been associated with HNPCC (hMSH2, hMLH1, hMSH6, 
hPMS1, hPMS2, hMLH3 and EX01), mutations in three of these (hMLH1, hMSH2 and 
hMSH6) are currently considered to predominantly cause HNPCC (Robinson et al 2007; 
Abdel-Rahman et a12006; Jarvinen 2003; Miyaki at a11997; Lindblom et a11993; Peltomaki 
et al 1993). Gennline mutations of hMLHl and hMSH2 account for approximately 90% of 
all HNPCC cases (Shulmann et al 2002). Phenotypic variation exists between genotypes, 
with hMLHl associated with a lower risk of extracolonic cancers than hMSH2 (Yu et al 
2003). hMSH6 mutations are associated with a later onset of disease, higher incidence of 
endometrial cancer and lower incidence ofCRC (Abdel-Rahman et a12006; Yu et aI2003). 
2.2.5 Risk of different cancers in HNPCC 
HNPCC is predominantly characterised by a high risk of early-onset (mean age of onset 20 
years earlier than that for sporadic) cancer in the colon (Abdel-Rahman et al 2006; Lynch 
and Lynch 2000), with a higher lifetime risk for CRC in males (69%) than females (52%) 
(Hampel et al 2005). Individuals who have inherited gennline mutations have an additional 
increased risk for extracolonic tumours. These include endometrial, stomach, ovary, small 
bowel, brain and hepatobiliary and urinary tracts (Lynch et al 1998; Vasen et al 1999; 
Mecklin and Jarvinen 1991). Of these cancers, endometrial cancer is the most common 
cancer after colorectal, with 30-50% of females affected by the age of 70 years (Strate and 
Syngal 2005). The overall prognosis for HNPCC-related CRC is suggested to be better when 
compared to non-hereditary (sporadic) CRC (Watson et aI1998). 
2.2.6 Early detection and prevention of HNPCC 
Interval surveillance for colorectal, endometrial (women) and possibly other HNPCC-related 
malignancies are recommended for patients with strong clinical evidence or a definitive 
molecular diagnosis of HNPCC (Lynch and de la Chapelle 2003). CRCs occur proximal to 
the splenic flexure, with one third of the cancers occurring in the caecum, thereby mandating 
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Surveillance studies have established that HNPCC adenomas are more aggressive and 
undergo an accelerated malignant transformation when compared to sporadic adenomas (Yu 
et al 2003). More frequent coionoscopic surveillance is thus justified for individuals at risk 
ofHNPCC than in the general population (Yu et a12003; Lynch et aI1996). 
In HNPCC the cancer incidence rises significantly after the age of 20-25 years (Jarvinen 
2003). The ICG-HNPCC proposes that the surveillance of the colon be initiated when the 
patient is 25 years old, or 5 years prior to the onset in the youngest affected family member, 
and should be repeated every 1-3 years. In SA screening is recommended biennially until 30 
years of age and annually thereafter. with polyps being removed when seen on colonoscopy 
(Goldberg et al 1998). Extracolonic investigation, especially surveillance of endometrium 
and ovary, is also indicated, though endometrial and ovarian cancer surveillance is less well 
established than that of CRC (Strate and Syngal 2005; Lynch and de la Chapelle 2003). In 
addition, screening for cancers that have occurred in other family members is a reasonable 
precaution to be considered (Strate and Syngal 2005). 
A 15-year follow-up study of 252 patients found that colonoscopic surveillance and the 
removal of polyps reduced CRC by more than 50%. Mortality from CRC in patients at-risk 
and among mutation-positive individuals could also be shown to be reduced by 
approximately 65% (Jarvinen et al 2000). Benefits of surveillance are further supported by a 
study of the cost-effective analysis of CRC for mutation-positive individuals. The costs of 
surveillance when compared to costs involved without a surveillance strategy were found to 
be less. In addition to this, it was further concluded that CRC surveillance increases Hfe 
expectancy by seven years (Vasen et al 1998). 
2.2.7 Surgery 
If a mutation-positive individual develops CRC, consideration is given to surgical treatment. 
In affected patients with CRC, a subtotal colectomy is usually favoured over total colectomy. 
However, these patients are still at risk and require lifelong endoscopic surveillance of their 
rectal segment. Mutation-positive, asymptomatic individuals. also have the option of 
prophylactic subtotal colectomy (Lynch and Smyrk 1996). Prophylactic total colectomy 
offers little benefit over partial colectomy and is generally not recommended (Syngal et al 
1998). However, it may be considered in mutation-positive individuals. where poor 
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anxiety is apparent (Strate and Syngal 2005; Vasen and Morreau 2002). Prophylactic 
removal of uterus and ovaries can be considered following childbearing years (Schulmann et 
aI2002). 
2.2.8 Chemoprevention 
Currently, pharmacologic agents are not a substitute for routine screening or management 
strategies. Although such agents have been shown to reduce adenoma development and 
progression in patients with F AP or sporadic cancer, no data illustrates any benefit for 
HNPCC specifically (Abdel-Rahman et al 2006; Strate and Syngal 2005). Trials are 
underway evaluating the efficiency of celecoxib, aspirin and resistant starch on adenoma 
prevention in carriers ofHNPCC (Yu et aI2003). 
The recognition of a genetic cause of cancer is important. For patients, treatment for 
hereditary cancer may differ from that of sporadic disease and individuals with an increased 
risk should adhere to periodic screening. Cancer-screening recommendations are based on 
the patient's risk of developing cancer and offered to at-risk and mutation-positive 
individuals. Genetic testing for HNPCC is available to distinguish between individuals with 
a mutation, who require surveillance, and those without a mutation, who do not require the 
intensive surveiUence. The ability to identify mutation-positive individuals prior to the 
development of malignancy has made the provision of detailed information and psychosocial 
guidance prerequisites for genetic testing (Vasen and Morraeu 2002). 
2.3 GENETIC COUNSELLING AND GENETIC TESTING FOR HNPCC 
2.3.1 Genetic counselling 
Previous definitions for genetic counselling have been considered too cumbersome and 
lacking in acknowledging the counselling elements (Biesecker and Peters 2001). A current 
definition is given by the National Society of Genetic Counsellors and describes genetic 
counselling as a process of aiding individuals in understanding and adapting to medical, 
psychological and familial implications of genetic contributions to disease (Resta et al 2006). 
The fundamental principles include: 
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.. Facilitating patient education in terms of the genetics, testing options, management, 
prevention, ongoing research and available resources 
.. Counselling of clients to enable an infonned decision concerning their choices and 
adaptation to the risk or condition (Rests et al 2006). 
The expansion of genetic counselling into cancer genetics is most probably due to a strong 
public interest and to the medical advances leading to the early detection or prevention of 
cancer in individuals at a high hereditary risk (Bennet et al 2003). While it is based on the 
geperal principles of genetic counselling, it differs significantly with respect to medical and 
psychological impact, the levels of risk that result from the genetic factors and the efficiency 
of surveillance and prophylactic measures (Weil 2000). Additionally. cancer-screening 
recommendations are provided in a directive manner, a departure from the traditional 
philosophy of non -directive genetic counselling (Bennet et aI2003). 
The recent identification of gene mutations involved in hereditary cancers has led to the 
increase in use of DNA testing in the management of familial cancer disorders and genetic 
testing for cancer susceptibility is available for some families with a history of cancer (Strate 
and Synga12005; de Wert 1998). 
2.3.2 Genetic testing 
Genetic testing includes two aspects: diagnostic and predictive testing. Diagnostic testing 
refers to testing for a genetic mutation in an affected individual. It is very similar to 
conventional medical diagnostic testing, as both involve the provision of definitive results on 
the patient's existing condition. Although the infonnation may have implications for the 
future, it largely reflects the patient's present health status. The tenn, predictive genetic 
testing, refers to the examination of genetic material with the aim of providing future health 
related infonnation about the individual at a suspected high-risk (Evans et al 2001). The 
concept of predictive genetic testing and its consequences, to identifY individuals who are 
predisposed to a disease that has not yet developed, is a difficult one. Furthennore the 
uncertainty about whether or not the condition will develop, when it will appear and how 
severely it will manifest itself adds to the complexity of predictive testing (Aktan-Collan et 
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Due to the complexities associated with genetic testing, in addition to its effects on the 
patient together with the implications for the family, pre and post-test genetic counselling is 
integral to the genetic testing process (Ensenauer et at 2005). 
In HNPCC, genetic testing starts with an affected individual who has been diagnosed with an 
HNPCC-related cancer. If a mutation is identified in a MMR gene (diagnostic genetic 
testing), predictive genetic testing can be offered to the individual's family members. as they 
are at-risk of carrying the mutation. Testing negative for a known mutation indicates that the 
individual is not at an increased cancer risk. However, if genetic testing does not identify a 
mutation in an affected individual, the results are uninformative and all members of such 
families are advised to adhere to high-risk surveillance recommendations. For these families, 
genetic testing does not help determine which relatives mayor may not be at an increased 
risk for developing HNPCC-related cancers. 
2.3.3 Ethical aspects of genetic testing 
The literature states that the provision of conditional information given in relation to future 
illness is not strictly defined (Chapman and Bum 1999). However, the general principles of 
medical ethics: autonomy, beneficence, nonmaleficence, justice and confidentiality outline 
the importance of informed consent prior to genetic testing (Beuchamp and Childress 2001). 
The principle of the right to choose whether or not to proceed with testing requires adequate 
and sufficient information to be given to the patient to allow for an informed independent 
decision. The principles of doing good and not harm require the informed consent to disclose 
all benefits, limitations as well as possible risks of the testing. Justice and confidentiality 
relate to the nondisclosure of the individual's genetic information to third parties (Ensenauer 
et a12005; de Wert 1998). Genetic counselling and predictive testing should, where possible, 
be undertaken by those with experience to ensure that these issues of confidentiality and 
information provision are explained within the consent process (Vasen et at 2005). To 
request or decline testing is ultimately the patient's choice. The benefits and risks must be 
considered in terms of their personal and family history to ensure that a decision compatible 
to the counselee's beliefs, values and priorities, can be made (Ensenauer et aI2005). 
The appropriate age for predictive testing is assessed on the age of expression of the disease. 
If medical benefits of testing are not apparent in childhood, testing is postponed until such an 
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herlhimself. In the context of HNPCC, predictive testing is usually only offered to 
individuals over the age of 18 years. 
Genetic information does not only concern the individual's genetic identity. however it is 
also significant to family members as it reflects their disease probability. A duty to warn 
family members following the diagnosis of a familial cancer also needs to be discussed with 
the individual receiving counselling and testing (Jarvinen 2003). Legal precedent has implied 
that individuals are responsible for the dissemination of their own medical information. 
However, the general agreement is that if the individual is unwilling to disclose hislher result 
in view of the implications for other family members, the harm caused by the failure of 
disclosure may outweigh the harm resulting from disclosure (Ensenauer et a12005; National 
Society of Genetic Counsellors Position Statement). 
2.4 Motivation for predictive testing in individuals from high-risk families 
Individuals have been found to display several motives for requesting predictive testing. 
Claes et al (2004) assessed the motivation of 19 mutation-positive and 21 mutation-negative 
individuals with self-report questionnaires, following predictive testing. This Belgium study 
found the most important motives to be: early detection of cancer, the knowledge of their 
children's risk and the opportunity to reduce uncertainty. Similar findings were reported for , 
American patients in a study by Espien et al (2001), where primary motivations included 
wanting to know if more screening tests were needed, obtaining information on the risk to 
offspring and certainty about their own risk. 
Knowing one's genetic risk, for the hereditary cancer, can facilitate early detection and 
prevention of the cancer (Marteau and Lerman 2001). However negative psychological 
sequelae may develop. particularly among individuals who learn that they are personally at 
an increased risk for developing disease or passing on cancer predisposing genes to their 
offspring (Lerman et at 1998). The amount of literature on the emotional reaction relating to 
genetic counselling and testing has only recently started to increase, with focus on cancer-
related worry often used as an outcome variable in such studies (Watson et al 2005; 
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2.5 Impact Of genetic counselling and genetic testing 
For genetic counselling to be considered effective. it should improve an individual's 
accuracy concerning the perceived likelihood of developing cancer and hislher knowledge of 
the disease genetics, with no adverse emotional impact (Braithwaite et al 2006). The distress 
and health-beliefs before and after genetic counselling for families at risk for HNPCC were 
investigated by Keller et al (2002) in a German study of 65 counsellees. Their results suggest 
that the individual's distress and worries related to HNPCC can be decreased by 
comprehensive counselling, whereby information conveying the benefits of early detection is 
addressed. Keller et al (2002) also found that by helping the counsellees absorb the 
information in the context of their personal cancer experience, the threatening aspects of 
HNPCC-related distress appeared to be reduced. 
It is important that cancer-specific distress is reduced with genetic counselling as depressive 
symptoms may have an impact on genetic test acceptance (Lerman et al 1998). Keller et al 
(2002) recommended promoting an individual's sense of control and confidence in the 
effectiveness of early detection as a measure to reduce the perceived threat associated with 
HNPCC-related cancers. 
Persons at risk for HNPCC are advised to have regular colorectal screening, and studies have 
shown that this reduces morbidity and mortality from CRC (Jarvinen et a12000; Vasen et al 
1998; Jarvinen et al 1995). The adherence to such advice prior to genetic testing is 
suboptimal. In order to optimise surveillance practices, screening is targeted at those 
individuals identified as mutation carriers, following predictive testing. Ideally, knowing 
ones genetic status allows for focused screening and medical management of these mutation-
positive individuals (Aldan-Collan et al 2001). Hadley et al (2004) assessed the impact of 
genetic counselling and testing on the use of and adherence to screening recommendations in 
56 asymptomatic at-risk individuals from American families known to carry a HNPCC 
mutation. At a follow-up of 12 months. it was demonstrated that genetic counselling and 
testing did influence adherence to screening guidelines. Recommended guidelines included 
increased screening for mutation-positive individuals and discharge from intensive 
screening, for those testing negative. The study found that 87% of mutation-negative 
individuals adhered to recommended guidelines, as compared to only 65% of mutation-
positive individuals. However. a slight increase (41 to 53%) of colonoscopic surveillance 
was found among mutation-positive individuals following the genetic testing. Wagner et al 
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individuals in the long term (average follow-up time 3.5 years), and found genetic testing 
largely improved screening compliance. Prior to genetic testing 31 % of these individuals had 
regular colonoscopies, following the testing this increased to 88%. 
Liljegren et at (2004) investigated the psychological aspects related to genetic counselling 
and the influence of a Swedish surveillance programme in at-risk individuals. They found 
that the high-risk group of asymptomatic mutation-positive individuals, while compliant with 
surveillance programmes, underestimated their personal risk of developing cancer. Aktan-
Collan et at (2001) studied 268 participants in a Finnish population to investigate the 
comprehension of their cancer risk, following predictive testing for HNPCC. The study was 
based on questionnaires completed three times during the procedure, including, the time 
prior to the frrst counselling session, one month and one year after test disclosure. The 
authors noted that nearly all the respondents correctly recalled whether or not they had 
inherited the mutation predisposing them to cancer. However. for mutation-negative 
individuals the recall of their post-test risk of developing cancer was understood more often 
than for mutation-positive individuals. Following the questionnaire, one-year post-test, 90% 
of mutation-negative individuals could correctly state their risk compared to only 36% of 
those who were mutation-positive. Amongst those with a mutation, misunderstanding was 
more common among the elderly and the less educated. Interestingly, the mutation-positive 
individuals who understood their result were significantly more worried about their risk of 
developing eRC than those mutation-positive individuals who did not understand the test 
result correctly. Contrastingly, this was just the opposite in the mutation-negative group. 
2.5.1 Risk perception 
Individuals may misinterpret risk figures by placing different emphasis on the numbers 
presented to them. The manner in which individuals interpret their particular risk of 
developing cancer will depend on their life experience. their attitude to life in general and 
their personality type (White and Mackay 1999). The response to risk information will also 
depend on how they perceive the illness, together with the test and its results. 
Risk is a numerical concept, and usually defined in terms of probability. Determining the 
probability that an individual is carrying an inherited mutation is only part of the risk 
assessment (Eiser 1998). The other probability is the likelihood of the mutation-positive 
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infonnation involve the individual's own interpretation of what they are told by the expert 
(Biser 1998). 
Understanding how an individual perceives his or her risk of developing cancer is complex. 
One such aspect is the individual's experience with cancer. This may lead to certain 
knowledge on the disease, which could contribute to risk perception regarding cancer 
(d'Agincourt-Canning 2005). Observing the impact of cancer on another person makes the 
disease and its meaning more real and often leads to a personal reflection about an 
individual's own risk of developing or passing on cancer (Murphy 1999). It has been 
recognised that individuals with an affected parent perceive cancer risks as higher than those 
without an affected parent (van Oostrom et aI2006). As for many common diseases, having 
a family history is the strongest predictor of lifetime risk, and perceptions of personal risk 
have been found to be exaggerated in individuals with a family history. A study by Keenan 
et at (2003) found that women with a family history of breast cancer used their individual 
experiences as a reference point in evaluating and interpreting their own cancer risk. Woman 
relied more on these experiences than on statistical probability to interpret their genetic risk 
and guide decisions for health-related management. Similar fmdings were reported for CRC 
in a study conducted by McAllister (2002) who found that the participant's understanding of 
cancer risk appeared to result from experiences of and interpretation of their family history 
. rather than the actual pattern of cancer within the family. 
2.5.2 Psychosocial aspects of genetic testing 
Meiser et al (2004) investigated the psychological impact of predictive genetic testing for 
HNPCC in 114 individuals, 32 of whom were mutation-positive and 82 mutation-negative. 
Only individuals who had never had a CRC or any of the cancers associated with HNPCC 
were included in this Australian study. The data illustrated that predictive testing amongst 
those who were mutation-negative led to psychological benefits and that no adverse 
psychological outcomes were found amongst mutation-positive individuals, one-year post-
test results. This was in keeping with the findings from a study perfonned in the United 
States (US) in which 155 participants were also followed-up over a year period subsequent 
to their involvement in a genetic testing programme. 
Gritz et al (2005) reported on the long-teon psychological responses following genetic 
testing for HNPCC among American individuals with and without a personal history of 
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status, was found in response to their genetic test results. Asymptomatic mutation-positive 
individuals however, did experience an increase in anxiety and depression immediately after 
the disclosure of their test result. This was found to decrease over the one-year period. 
Additionally it was also found that the perceived risk of developing CRC among mutation-
positive asymptomatic participants was raised following the test results and remained 
elevated during the observation period. Gritz et al (2005) found those individuals with higher 
levels of baseline distress (prior to testing). lower quality of life, and fewer social support 
systems to be at risk for increased short and long-term distress. 
Claes et al (2004) studied the short-term psychological impact of predictive testing for 
HNPCC in 40 individuals and found the distress level to be within normal ranges one month 
after test disclosure. The distress remained the same over the pre and post-test period for 
mutation-positive and negative individuals, while a decline was noted for mutation-negative 
individuals following their results. Further investigation into the impact of predictive testing 
for HNPCC was conducted by Claes et al (2005), in a clinic-based genetic testing 
programme. This study evaluated the illness representation, distress and health-related 
behaviour in 72 individuals (36 were mutation-positive and 36 mutation-negative). Distress 
levels were higher in mutation-positive individuals than mutation-negative, with the level of 
cancer-related distress shown to be low to moderate, however this decreased from pre to 
post-test in both groups. Findings further revealed that 53% of mutation-positive and 20% of 
the mutation-negative individuals reported at least one disadvantage with knowing their test 
result. The main disadvantage for mutation-positive subjects was the need for regular 
screening and the psychological burden. For mutation-negative subjects, it was the reaction 
of their relatives when disclosing a favourable result. 
An individual's perception of disease can have an important impact on both their emotional 
response and health-related behaviour. Claes et al (2005) reported on such health-related 
behaviour in their study. Twenty-seven out of the thirty-six mutation-positive participants 
had a colonoscopy within the first year following their test disclosure. Three did not have a 
colonoscopy but were younger than 25 years, and not strictly due for examination, and six 
had had a colonocopy prior to testing. The authors concluded that all the mutation-positive 
individuals were thus adherent to the recommendations of the screening procedure if 
accounting for a maximum interval period of two years. None of the mutation-negative 
individuals had a colonoscopy within the first year. however about a third intended to have 
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some mutation-negative individuals to be concerned regarding the discharge from 
coionoscopies. 
As further long-term information on the psychological impact of predictive testing was 
needed to fully assess such programmes, Collins et al (2007) conducted a three-year follow-
up study of Australian participants. The study included 19 mutation-positive and 54 
mutation-negative individuals. Psychological measures were used, consisting of baseline 
assessment and follow-up periods of 2 weeks, 4 months, 1 year, and three years after test 
disclosure. As had been previously reported, an increase in mean cancer distress could be 
shown in mutation-positive individuals at two weeks. This returned to normal baseline in 12 
months (Collins et aI2007). The authors found that this level was maintained over the three-
year period. Mutation-negative individuals illustrated a sustained decrease after testing. All 
mutation-positive and 7% of the mutation-negative group had had a colonoscopy by the end 
of the three-year period. 
2.5.3 Illness representation 
An individual's representation of illness is defined as a dynamic entity shaped from a variety 
of sources, which are important when considering reactions to health threats. These may 
develop from direct experience of the illness and associated medical care, a family or 
friend's experience, and ideas relating to cultural beliefs (Shiloh 2006; Leventhal et aI2003). 
Theories concerning the response of an individual, to the potential of developing a life-
threatening illness and the reasoning behind the resultant health behaviour. are relevant to 
research relating to genetic testing (Gooding et al 2006). An investigation into the 
psychosocial aspect of genetic testing is crucial in the examination of individuals utilising 
genetic testing and their response to the genetic results. Gooding et al (2006) argue that 
theories that focus on stress and coping provide useful frameworks for studying genetic 
testing for adult-onset disease risk. One such theory is Leventhal's Common Sense model of 
Self-regulation (CSM), which highlights the importance of both a cognitive and emotional 
involvement in reacting to a health-threat (Leventhal et al 2003). This model posits that an 
individual's personal understanding of an illness, determines their coping response, health 
behaviour and psychological wen-being (Leventhal et al 2003). The relevance of such a 
model was noted by Shiloh (2006) in terms of specific recommendations that need to be 
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information processor rather than a passive receiver of given information, the following 
recommendations were made: 
.. To examine the understanding of genetics and heredity, in general, prior to any 
educational attempt being made in the session 
.. To explore specific representations that clients have concerning the particular 
genetic condition before trying to modify their knowledge and reactions 
.. To investigate the former experiences with genetic conditions using a personalised 
approach that would help facilitate the individual's meaning of the experience 
.. To clarify the role of self-representations and coping behaviours involved in the 
response to these threats and direct counselling in dealing with these issues 
.. To evaluate the costs and benefits of the client's misconception before trying to 
change them 
.. To consider the interaction of a cognitive and emotional aspect as predictors of 
coping with genetic conditions and risk 
Predictive genetic testing provides a very specialised type of genetic information. Insight 
into the potential impact of this information for individual's undertaking predictive testing 
for HNPCC is crucial due to the possible effect on distr~s and health-related behaviour 
(Claes et aI2004). This review highlights a few of these aspects that may have an impact on 
participants involved in these programmes. The literature included provides perspectives 
from developed countries such as the United Kingdom, US and Australia, and it will be 
























This chapter describes the research design in detail. Sections addressed include participant 
selection and description, instrumentation, data collection and analysis and the identified 
limitations and strengths of the research methodology. 
3.2 RESEARCH DESIGN 
A qualitative approach by means of a descriptive exploratory design were utilised for this 
study. 
Qualitative research offers the opportunity of providing insight into an individual's actions, 
beliefs. thoughts and perceptions that quantitative methods alone cannot (McMillan and 
Schumacher 200 1). This type of research has been particularly suited to understanding the 
"how" and "why" questions with the goal of attaining an insider's view of the group under 
study. An insider's view may explain how people perceive and react to a given health 
problem and what interventions, if any, are most likely to be successful (Ulin et al 2005; 
Holloway and Wheeler 1996). Qualitative methods are orientated towards discovery and 
process; illustrate a high validity, less concerned with generalisability, and more interested in 
obtaining a deeper meaning of the research problem in its unique context (Ulin et aI2005). 
Interviews were used to provide the participants with the opportunity to describe their 
experiences to the researcher. Popay (1992) states that the qualitative inquiry "explores the 
meaning people attach to their experiences and identifies and describes the social structures 
and processes that shape these meanings." 
The primary purpose of the study was to build rich descriptions of the circumstances that 
confront individuals following predictive testing for HNPCC. This is relatively unexplored 
in the literature. and thus a descriptive and exploratory study design was incorporated. The 
main purpose of a descriptive study is the acquisition of comprehensive and exact 
information about a particular fact, in light of providing new information on that specific 
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identify or discover important categories of meaning in poorly understood phenomena and it 
is usually conducted in new areas of inquiry (Marshall and Rossman 1999). 
The study focuses on the gathering of information from each participant. at one point in time. 
As it is a cross-sectional design, it does not capture changes over time as with a longitudinal 
study (McMillan and Schumacher 2001). Although this method lacks comparability over 
time, it is a less costly method used by researchers with limited resources, time and money 
(McMillan and Schwnacher 2001), as is the case in the present study.· 
3.3 PARTICIPANTS 
3.3.1 Sample size determination and selection 
Qualitative sampling consists of small sampling units studied in depth. The use of large 
samples does not enhance the research, but rather lacks the depth and richness of a smaller 
group, as the specific responses of the participants and their meanings may be lost (Holloway 
and Wheeler 1996). 
More than 400 families have been recruited into the South African HNPCC research 
programme. Disease-causing mutations have been identified in 30 of these families, 19 of 
which are currently involved in the predictive testing programme. The majority of these 
individuals live in the Western and Northern Cape Provinces. For the purpose of this study 
12 mutation-positive individuals from the Western Cape, who met the inclusion criteria (see 
3.3.3.1 below), were identified by the genetic nurse involved in the Colorectal Cancer Unit. 
These individuals were approached and those who volunteered were included in the study. 
3.3.2 Sampling method 
Convenience and purposive sampling was utilised in this qualitative study. Convenience 
sampling facilitates the selection of participants that are accessible to the researcher, 
permitting for time and distance limitations of the research project. Purposive sampling was 
chosen to select "information rich" cases to allow the researcher to identify particular types 
of cases for in-depth investigation (Neuman 1999; McMillan and Schumacher 2001). 
Furthermore purposive sampling is used when a few cases are studied in depth to yield 
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The sample group of 12 participants were chosen on the grounds of their mutation status 
rather than randomly selected from the predictive testing programme. The sample size was 
already limited due to time constraints, and only mutation,:"positive individuals were selected. 
As a general consideration when selecting sample size, the more heterogeneous the 
population, the larger the required sample size, it was thus a further consideration to limit the 
number of variables being studied (Rossouw 2003). 
3.3.3 Eligibility criteria 




Individuals over the age of 18, who have received their HNPCC predictive genetic 
test results and are mutation-positive; 
Individuals consenting to be interviewed and tape-recorded by the researcher; 
Individuals accessible for a personal interview and within a 100 km radius of the 
University of Cape Town. 
3.3 .3.2 Exclusion criteria 
o 
o 
Individuals who have received their predictive test results and are mutation-
negative; 
Individuals who have developed CRC. 
3.4 MEASUREMENT INSTRUMENTATION/OUTCOMES 
3.4.1 Data collection 
In-depth semi-structured interviews together with the researcher's observations were used to 
gather information for the study (Appendix III and N). The majority of the interviews took 
place in the participants' homes and were tape-recorded. 
Qualitative interviews provide the participants with the opportunity to describe their 
experiences in detail and to give their perspectives and interpretations of these experiences 
(Holloway 2005). A semi-structured interview schedule was used to collect similar types of 
data from all the informants in addition to allowing for the exploration of the participants' 
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interviewer and respondent whereby a structure, without compromising the open exchange, 
is created (UUn et al 2005). Furthermore it allows for control over the interview so that the 
purpose of the study can be achieved and the research topic explored (Holloway and 
Wheeler 1996). 
The majority of questions in the interview guide were open-ended to encourage free 
responses from the participants without the limitation of categories. Closed-ended questions 
were used to obtain the demographic information. Neutral probes were included to clarify 
responses if they were incomplete or misunderstood. Any non-verbal cues including the 
participant's facial expression. gestures or reactions that were present during the interview 
were noted. These were included in field notes. which were completed following the 
interview session, such that it did not take place in front of the participant. 
Questions included in the interview schedule were generated from the literature and 
discussion with the genetic nurses. The section on cancer knowledge was adapted from de 
Vries et al (2004) and Collins et al (2000). Questions from Aktan-Collan (2001) were 
incorporated amongst the other questions into the sections on personal understanding and the 
recall of cancer risk and subjective risk perception. The question relating to factors 
influencing the decision on the up-take of the genetic test, included in the section relating to 
the motivation for participation in the predictive testing programme, was adapted from Claes 
et al (2004). 
The validity of the interview schedule was reviewed by the colorectal cancer genetic nurse 
and the research supervisors, to ensure that the items were comprehensive and the 
sequencing was appropriate. The interview schedule, information sheet and consent form 
were available in English and Afrikaans. As the researcher is fluent in both languages, the 
interview was conducted in the language of the participant's choice. depending on their 
preference. Interviews did not differ in content for each interviewee. However the time of 
each depended on the individual response and ranged from 40 minutes to just under one and 
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3.4.2 Research setting 
The researcher requested that the interviews take place in the homes of the participants. 
Holloway and Wheeler (1996) suggest that the individual is more likely to be comfortable 
and less inconvenienced in their home, when asked to talk about issues, which they might 
find sensitive. Furthermore a dialogue with a person in their natural surrounding will reveal 
gradations of meaning from which their perspectives and definitions are continually shaped 
(Marshall and Rossman 1999). By interviewing the participants in their home environment, 
the researcher could see the setting, and better observe the family interaction and behaviour. 
For those participants where it was not convenient to be seen in their homes. interviews were 
conducted in a private venue of their choice. Five subjects, including the two pilot 
interviewees, elected to be seen in a private room at their local clinic. 
3.5 PROCEDURE 
The genetic nurse involved in the Colorectal Cancer Unit at Groote Schuur Hospital (GSH) 
contacted the potential participants and . informed them of the study. Consenting individuals 
were then contacted by the researcher to arrange the interview times and venues. 
3.5.1 Piloting 
A pilot study was carried out on two of the participants to refine the structure of the 
interview schedule and to identify any changes needed to improve the clarity and format. 
Questions were tested for difficulty of comprehension and to ensure that answers elicited the 
type of information envisaged (Roussow 2003). Following each interview the researcher 
asked the interviewees for their critical analysis on any confusing categories or any other 
aspects of the schedule, which could be considered insightful (Roussow 2003). Several 
questions were adapted to eliminate the ambiguous nature and to aid the clarity of the 
interview schedule. Subsequent to these corrections, the shedule was rechecked by the 
researcher's supervisors. The information used in the pilot study was not included in the 
study. However, in addition to serving as a pre-test of the interview schedule, it provided an 
estimate of the amount of time required to complete the interview with a mean time of 
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3.5.2 Recruitment 
Study participants were drawn from a group of individuals willing to share knowledge and 
experience related to the research topic CUtin et al 2005). Individuals were selected on the 
basis of having undergone experiences about which the researcher wanted to gain 
information. Potential participants meeting the inclusion criteria, accessible and likely to be 
willing to participate, were selected from the HNPCC database by the genetic nurse familiar 
with these individuals. As far as possible, individuals representative of a generalised broad 
base in terms of socio-economic status, education level and ethnic background were chosen 
and contacted via telephone by the genetic nurse, and invited to participate in the study. She 
then, with the permission of the individual, provided the contact details to the researcher. 
The researcher invited the first twelve consenting participants to participate in the study. The 
interview times and venues were subsequently arranged to suit the subject. 
3.5.3 Data collection 
Tape-recorded interviews allowed the researcher to capture the participants' words without 
having to write down what was being said. which would have interfered with the 
researcher's engagement with the participants. Each tape was dated and labeled with a code 
and the participants' names were kept separate from the tapes and interview schedules. to 
which only the researcher had access. Reassurance was provided to the participants that the 
information discussed would be kept confidential apart from the possibility of being 
published in a scientific journal where names would not be used. 
Each interview took place in a private venue of the participant's choice. The researcher 
conducted each interview personally during the months of March and April 2007. Some of 
the questions in the interview schedule may have revisited sensitive issues and individuals 
were given the option of further counselling following the interview, to address any distress 
caused by talking about their experiences. None of the interviews exceeded an hour and a 
half and the need for a second interview was not requested by any of the participants. 
It is acknowledged that, before analysis of the data can take place. the researcher must 
preserve the words of the individuals they have interviewed as accurately as possible 
(Holloway and Wheeler 1996). Therefore, the transcription of the recorded interviews 
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Following the recording of the interview. the schedule was transcribed by an official 
university transcriber (in either English or Afrikaans). in preparation for the data analysis. 
3.6 DATA ANALYSIS 
The method of analysis used was based on the constant comparative method of Glaser and 
Strauss (1967). Content analysis was used to organise the data collected from the interviews 
in a manner that facilitated the identification of emerging concepts and themes. Although 
several topics had been predetermined based on the structure of the interview schedule, 
themes within these topics and their relatedness to one another could emerge from the 
interview rather than hypotheses being created, a priori. 
Data analysis facilitates the process of bringing order, structure and interpretation to the 
mass of collected information (Roussow 2003; Holloway and Wheeler 1996). The researcher 
recorded the interviews to preserve the data and meanings on tape, which allowed for the 
analysis to be completed subsequent to the interviews. As the analysis was done following 
the communication process. the data could be analysed without influencing the 
communicator in any way (Roussow 2003). 
Once the recordings were transcribed, the coding of the data, which fragments the interviews 
into separate categories, allowed for the raw data to be processed (Rubin and Rubin 1995). 
The coding was then discussed with the researcher's supervisors before further analysis took 
place. Breaking the material down into manageable sections allowed for the constant 
comparing and contrasting of categories to identifY patterns of meaning (Holloway 1997). 
The transcripts were read through several times, and the content elicited was compared with 
the earlier collected data. Each category reflected a concept being analysed to describe the 
participants' understanding and impact of the predictive testing programme. The 
interviewee's responses where then grouped into categories of similar ideas and concepts. 
These categories were then explored to identifY any further significant themes, recurring 












CHAPTER 3: METIIODOLOGY 
3.7 TRUSTWORTmNESS AND VALIDITY 
Lincoln and Guba (1985) suggest that the fundamental criterion for a qualitative report is 
trustworthiness and that the criteria for judging qualitative data include credibility, 
dependability, confumability and transferability (Ulin et al 2005). By ensuring the 
trustworthiness and thus validity of the study it ensures that an appropriate meaning is 
derived from the specific deductions made, following data analysis. 
3. 7.1 Credibility focuses on the confidence in the truth of the fmdings of the study and the 
provision of an accurate understanding of the context (Ulin et al 2005). This study utilised 
peer debriefing in an attempt to ensure credibility. The researcher regularly met with her 
neutral co-supervisor to analyse and interpret her data. 
3.7.2 Dependability: According to Holloway (1997), for the study to be dependable it should 
illustrate consistent and accurate findings. A detailed description of the research method is 
thus given to ensure the decision trail is clear, process is consistent and results are 
dependable (Holloway 1997). 
3. 7.3 Confirmability: The attempt of the researcher to maintain the distinction between her 
personal values and those of the participant's, ensure that the findings are the result of the 
research and not the biases or subjectivity of the researcher. The researcher mechanically 
recorded the data to enhance the validity by providing an accurate and complete record 
(McMillan and Schumacher 2001). Additionally, the genetic nurse and qualitative researcher 
reviewed the interview guide to ensure that questions were easily understood and applicable 
to the participants. 
3.7.4 Transferability relates to the conclusions of the study and their transferability to other 
contexts. The goal of transferability is to produce data which can be applied to other contexts 
if samples are selected to represent viewpoints and experiences that reflect key issues in the 
research problem (Ulin et al 2005). The use of comprehensive descriptions will enable peers 












CHAPTER 3: MElHOOOLOGY 
To further certify that the findings of the qualitative study represent reality, the content 
analysis was verified by the research supervisors to ensure minimal research bias in the 
interpretation and categorisation of the data. The use of the pilot study together with the 
supervisors' comments on the validity of the interview schedule ensured further 
trustworthiness (Holloway and Wheeler 1996; McMillan and Schumacher 2001). 
3.8 ASSUMPTIONS 
The researcher assumed that each participant answered questions as honestly as possible and 
expressed a true reflection of their experience. 
3.9 LIMITATIONS AND STRENGTHS OF THE STUDY 
3.9.1 Limitations olthe study 
.. Time constraints due to the course design. As in-depth interviews produced a rich 
source of data, it was necessary to restrict participation in the study to a small 
sample size. By using this approach the intention is not to make generalisations, and 
findings are only valid for populations with similar characteristics; 
.. The use of a cross-sectional design meant that changes to the participant's 
understanding and impact of the predictive test could not be assessed over time. It is 
possible that certain views could change fonowing further contact with the 
clinical/genetic team; 
.. Selection bias: individuals who chose to participate may be unrepresentative of the 
target population; 
.. The researcher is aware that her counselling skills are limited and that a sufficient 
rapport facilitating the full disclosure of sensitive information may not have been 
established. The participants may also have provided answers, which they thought. 
may have been appropriate rather than that of their true attitudes (Holloway 1997); 
• As the interview schedule was based on the literature, counsellor's opinion and input 
from the genetic nurse and supervisors, the questions may have missed relevant 
points from the participant's perspectives; 
• Minimal international literature and absence of South African literature implies that 
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3.9.2 Strengths of the study 
• The researcher was not part of the clinical/genetic team known to the individuals 
involved in the predictive testing programme. The individuals were thus probably 
more likely to speak honestly and openly about their experiences; 
• Each interview was conducted personally by the researcher in a venue of the 
participant's choice and in a language that they were familiar and comfortable with; 
• Certain questions used were from other validated studies which increased the 
trustworthiness of the study; 
• The use of a semi-structured interview enabled the researcher to focus on issues 
salient to the participants. Open-ended questions facilitated responses that were not 
limited to pre-set categories. Furthermore, clarification could be sought and allowed 
the researcher to explore or probe issues of interest; 
• By tape-recording the interviews, the exact words of the participants were captured, 
and the researcher could provide her full attention to what the participant was 
saying; 
• Research bias: The researcher was conscious of her own assumptions and recorded 
her experiences and thoughts during each interview, to try and overcome any 
potential bias associated with her subjectivity on the information obtained. 
3.10 ETHICAL CONSIDERATIONS 
The research project maintained the ethical principles of participant autonomy, anonymity, 
confidentiality and respect. Approval was obtained from the Department of Research and the 
Institution of Research and Ethics, of the Faculty of Health Sciences at UCT, prior to the 
study (REC REF: 427/2006). 
The genetic nurse involved in the initial contact of the selected participants explained the 
purpose of the research and participants were in no way coerced or persuaded into taking 
part in the study. The participants were assured that they could withdraw at any time without 
jeopardising any medical services that are available to them or their families at the clinic or 
hospital. Every possible avenue for protecting the anonymity of participants was taken, and a 
coding system was used to facilitate this. The researcher ensured the participants that the 
names and the information provided to her during the interview would be kept confidential. 
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All participants were 18 years and older, and legally competent to sign consent. Written 
consent was obtained prior to the interviews, from all participants except for one individual 
who was illiterate, where verbal consent was given. The participants were infonned that the 
session would be tape-recorded for which consent was also obtained (Appendix I and II). 
The audiotapes were kept in a locked filing cabinet that only the researcher had access to, 
and the tapes were destroyed as soon as the transcription process was complete. 
3.11 RISK BENEFIT 
The risk to participants was the discussion of emotional issues and personal concerns related 
to their perception of cancer. The researcher was sensitive to the emotional state of the 
individuals and ensured that confidentiality and anonymity was maintained following the 
disclosure of infonnation in the interview. Participants had the opportunity of a second 
session with the researcher to clarifY any questions or address emotional concerns, which 
had evoked anxiety. With their pennission, the researcher could additionally schedule a 
session with an experienced genetic counsellor. None of the participants felt they required a 
second session with either the researcher or genetic counsellor. 
The presentation of the analysis, findings and discussion are intennixed in Chapter Four. 
This is customary in qualitative research (McMillan and Schumacher 2001) and subtitles are 
included to connotate the different fmdings. This facilitates the description and prevents 






















CHAPTER 4: ANALYSIS, RESULTS AND DISCUSSION 
CHAPTER FOUR 
4.1 INTRODUCTION 
This chapter provides information on the sociodemographic and socioeconomic backgrounds 
of the participants. The data obtained from each interview are presented and discussed in 
sections and compared to the available literature, where applicable. A total of ten interviews 
were conducted and transcribed for the data analysis. 
The data-analysis involved the coding of various sections and identification of categories and 
themes, as described in the research methodology. Direct quotes are included from the 
participants' interviews to provide the reader with a greater insight into the information and 
to enhance the validity of the identified themes. If a participant's response required 
translation from Afrikaans to English, it has been indicated, after the quote. 
To ensure confidentiality and anonymity, participants (P) are replaced by coding numerals. 
4.2 SOCIODEMOGRAPmC DATA 
Participants ranged in age from 24 to 55 years. The majority of participants were females 
and of mixed ancestry. The sociodemographic and socio-economic information for the ten 
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Table 4.1: Sociodemographic and socioeconomic information for participants (n=10). 
1 Male 49 Single 
1 Female 32 Single Grade 12 Full-time 
3 Female 24 Single Grade 12 Full-time 
4 Female 49 Married Grade 12 Full-time Bookkeeping 
5 Female 50 Single Grade 5 Full-time Cleaner 
(; Female 24 Single Grade 11 Unemployed N/A 
7 Female 24 Married Grade 10 Full-time 
8 Female 44 Married No schooling Full-time Domestic worker 
9 Male 24 Single Grade 11 Full-time Labourer 
10 Female 55 Divorced Grade 12 Full-time Nurse 
The level of education was high among most of the participants. In South Africa, formal 
schooling comprises of 12 years of primary and secondary education. High school ends at 
Grade 12, otherwise known as standard ten or matric. Half of the participants had 
matriculated and three had a tertiary education. Of the participants who had completed 
secondary school, four of the five had taken biology as one of their main subjects. Only P5 
and P8 did not complete primary school (seven years of schooling) and for P8, the school 
had been inaccessible, as she had grown up on a farm away from the rural town. 
The ten participants reported a range of monthly household incomes, and all except for one 
(P6), had a full-time job. According to Statistics South Africa (2004), the average annual 
income per household for Cape Town is R 87 811 (R 7 317 per month). Seven of the 
participants had an income below this amount and the most disadvantaged participant had a 
household income of Rl 600 or less to support five people. Thus the socioeconomic status 
for the participants in this study was relatively low (Table 4.2), with the exception of PI and 
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Table 4.2: Number of individuals dependent on the monthly income (n=10). 
R25 601 -RSI 200 3 
2 Rl 601 - R3 200 4 
3 R6 401 - R12 800 3 
4 R25 601- RSI 200 6 
5 R801 - Rl 600 5 
6 N/A* 
7 Rl 600 - R3 200 5 
8 R3201-R6400 5 
9 R3 201 - R 6 400 6 
10 R3 201 - R6400 3 
tP6 did not know the household income/month; she was unemployed at the time of the study and 
not earning an income. ·The residence provided boarding for 17 individuals, none of whom were 
related to P6. 
4.2.1 Family history of cancel' 
The feature that differentiates genetic disorders from other illnesses is the implications for 
other family members (Murphy 1999). The majority of counselees are aware of genetic 
testing due to having a family member with cancer, and thus upon initiating counselling may 
already have strong emotions relating to their experience within their own family (Weil 
2000). 
Part of each interview focused on obtaining information relating to the participant's family 
history of HNPCC. Data were gathered on the number of and relationship to relatives with 
an HNPCC-related cancer. This was obtained from the HNPCC database in the Division of 
Human Genetics at UCT, and questions from Section A of the interview schedule. Table 4.3 
illustrates a few of the important aspects relating to the HNPCC-related cancer in the 
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Table 4.3: Experience of cancer in the family and involvement in a genetic testing 
programme (n=10). 
Affected Parent tested Parent died Realised tbat No. of 
parent forMMR due to tbey were at risk cbildren 
(CRe) mutation cancer forCRC involved in 
P predisposing predictive 
toHNPCC testing 
programme 
1 Mother Yes Yes As teenager, due N/A 
to grandmother's 
cancer 
2 Father Yes Yes With father's Tooyoung* 
involvement in 
programme 
Related to father's 




4 Mother Yes No enrolment in 1 child 
programme and tested 
contact with 2 tooyoung* 
genetic team 
S Father Yes Yes 2 children 
With testing 
not tested 
6 No Yes No When approached 
for testing 
Tooyoung* 
7 Father Yes Yes Due to father's 
involvement in Tooyoung* 
programme 
1 child 
8 Mother. No Yes When mom and tested 
sister had cancer 1 not tested 
Hoo 
Related to father's 




When mother had 1 child 10 Mother Yes Yes been diagnosed tested 
and involved in 1 tooyoung* 
programme 
... Predictive testing is only offered to individuals over the age 18 years. The age limit has been set 











CHAPTER 4: ANALYSIS, RESULTS AND DISCUSSION 
When asked about the time when they had realised that they were at risk for CRC, eight of 
the ten participants stated that it had been as a result of the diagnosis of a parent's HNPCC-
related cancer and! or a family member's involvement in the genetic testing programme. PS 
and P6 had only realised the risk factor subsequent to their own involvement in predictive 
testing. PI recalled that this had been around the age of 13 years. His grandmother had had 
cancer, and he realised that due to the family history, he was also at risk. For the other 
participants, the realisation had been much later, from an age of 19 years and older. All the 
participants, excluding P6, had grown up with an affected parent. The mother of P6 was 
unaffected, however she had a maternal grandmother (now deceased) and maternal uncle 
who were affected. 
Predictive testing is only possible following the identification of a mutation in an affected 
family member. For all the participants with an affected parent, the disease-causing mutation 
had been identified in the respective affected parent. The mother of P8 had passed away 
prior to any genetic testing and her older affected siblings had been tested. Pl. P2. PS. P7. P8 
and PIO had lost a parent as a result of the cancer. Although it had not been directly asked, 
many of the participants volunteered the status or the suspected mutation status of their 
siblings and extended family. Many of the participants' children had also consented to be 
tested for the familial CRC predisposing mutation (of those eligible for predictive testing; 
only PS's two children and P8's one child had not entered the programme. Table 4.3, page 
37). 
4.3 GENETIC TESTING 
4.3.1 Motivation/or predictive genetic testing 
Participants were asked to rate seven statements according to the extent that it had influenced 
their decision to have a predictive genetic test. The accumulated responses of the ten 
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Table 4.4: Participants' motivation for predictive testing (n=1O). 
1. To learn about my children's risk 6 4 
2. To reduce my risk of developing cancer 1 1 8 
3. To plan for the future 1 2 7 
4. To help research 10 
5. To be certain about my risk 2 8 
6. To make decisions about having children 2 3 5 
7. Marital decisions 2 1 6 
8. Doctor recommended it 2 4 4 
9. Family members urged me to take test 4 2 4 
IO.Worried about abnormal stoolslhealth related concerns 7 2 
The decision to have a genetic test was strongly influenced by the fact that the participants 
were concerned about their children's risk. All the participants who had children of their own 
viewed this as an important factor in their decision-making. 
P8 stated that the most essential reason for testing was for her children' s benefit and to be 
able to explain to them about predictive testing and the future surveillance required. P4 
commented: 
" ... the main thing was that we felt if we could prevent anything happening to our kids, we 
could stop it, because the more you know about a thing, the more likely you are to prevent it 
or find ways of preventing it and that was a big deal for us". 
For the majority of participants, future planning (7/10), reducing their risk of developing an 
HNPCC-related cancer (7/10), gaining certainty (8/l0) and aiding research (10/10) rated as 
further key motivating factors. PI was the only participant that viewed these items (2, 3,5 in 
Table 4.4) to have "no", or "very little effect" on his decision-making. The only factor that 
strongly motivated him to have the genetic test was to aid research. PI felt that he was 
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need to know his mutation status. He expressed that he felt the benefit of the research would 
not be for him, but rather for other people. 
" ... I was already goingfor check-ups and that sort of thing so you know, whether the blood 
test were going to reveal - I was already being tested anyway, so as far as I was concerned I 
was at the end of it anyway. Whatever benefits came out of the research stuff would not 
necessarily benefit myself but it may benefit other people ... " 
Eight of the ten participants did not express any health-related concerns, prior to the testing, 
to have strongly influenced their decision. However P3 was very worried about her health 
although, when asked if she was experiencing any symptoms, she commented that she had 
no physical symptoms. For P9, the health concerns were one of the factors that had played a 
large role in his decision-making concerning the uptake of the test. When asked if he had 
been apprehensive about any health concerns prior to the testing. P9 responded: 
"No not actually, but some days, I don't know if I was imagining it, but I felt lilce my bowel 
action was somehow different" (translated}. 
The participant also added that it was important for him to know his status. He reported that 
he had been extremely anxious due to the uncertainty. P9 recalled an experience prior to his 
involvement in the predictive testing programme where he felt not knowing was making him 
physically ill. 
" ... when I tried to stand-up, I felt ill all of a sudden and then I thought, this is where I could 
have known already. So it's about my health, that I need to know where I stand" 
(translated}. 
4.4 LEVEL OF UNDERSTANDING OF THE TEST RESULTS 
Participants were questioned about their understanding of the genetic test. Their responses 











Table 4.5: Participants' knowledge of cancer genetics (n=10). 
1 "Can not tell 
80% - will get it you if you have (GT)-"is about the risk factor". (C)- Family history and number of affected Yes unless pass away 
cancer, but can "identifies polyps". family members before the onset provide risks" 
1 80% - prevent it by a "Require GT to see if you have the 
Yes Yes gene or not", (C) "identifies changes to Test only healthy lifestyle colon wall", 
3 80% - but views it as 
(GT)- "can see if you are predisposed 
Yes No 
to bowel cancer", (C) - "checks that Family history 
a definite the regeneration and cells working 
normally" . 
.4 "Not a cancer 













5 No· GT - "tells you if you are a carrier" . 50% Yes (C)- "tells you if you are fine". Only test 
6 Yes 50% Yes (Gn - "looks for gene". (C)- Only test "identifies anything in the colon". 
7 Yes 50% Yes 
(GT) - "have gene or not". (C) - "can Family history 
see if the colon is OK". 
8 "NOm shows you 
Yes ·50010 - will get cancer, if you have the (GT) - "looks for gene". (C) - "looks 
Family and age is near that of other 
100% chance gene or not" for cancer in colon" . affected family members 
9 80010 - feels this has 
Yes been reduced as Yes 
(GT) - "looks for cancer gene". (C)- Family history 
colonoscopy showed "identifies lesions in colon wall". 
no polyps 
10 (GT) - "see if cancerlfB/other 
Yes 50% - but will Yes problems". (C) - "can identifY gene, if Family history develop it have the gene must have an operation" . 
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All the participants in the study could recall their approximate dates of counselling and 
result-giving session, as well as the geneticist who had been involved in delivering the 
results. For the majority of individuals, the person who had created the awareness of the 
availability of a predictive test had been the nurse or doctor involved in the programme. 
Only P3 and P6 had initially heard about the possibility of a predictive test through a family 
member, which in this case had been the affected father and aunt, respectively. 
Upon being asked if there were any additional factors (independent of the genetic test result) 
that they had felt may have increased their risk, six participants (PI, P3. P7 - PIO) viewed 
their family history as a factor. PI mentioned the number of affected individuals in his 
family, in addition to the family history. P8 indicated that being of similar age to the onset of 
the affected family members was a further indication that she was at high-risk for the eRe. 
All the participants correctly stated that they were mutation-positive. When asked how the 
predictive test was conducted, all of them accurately recalled that it had been a blood test. 
One of the specific aims of the research was to investigate the understanding of the 
predictive test. The ten participants demonstrated different levels of understanding and 
responses ranging from a very basic to a high comprehension. Questions relating to the 
genetic test in terms of: risk of developing eRe with a mutation-positive result; if the 
genetic test was capable of detecting cancer or not; and the difference between the genetic 
test and a colonoscopy are presented in Table 4.5 (page 41). 
All the participants could explain that their mutation-positive result had placed them at an 
increased risk for developing eRe. However, only seven participants (PI-P4, P7-P9) 
realised that being mutation-positive implied that their risk of developing cancer was 
consequently higher than the general population. P5 and PIO thought it was the same, and P6 
did not know. The estimated risk expressed by the participants, differed among the group. 
PI, P2, P3 and P9 recalled an 80% risk. However, P9 who identified his risk to be 80%, felt 
that after having a colonoscopy showing no polyps, this could be reduced. 
P4, P5, P6, P7, P8 and PIO quoted 50%, as the estimated lifetime risk of developing eRe. 
However P4 felt she had a positive outlook and did not intend developing cancer. PI, P3, P8 
and PIO added that they felt that they would definitely develop cancer. PI further expressed 
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"... the risk is there, and the risk is that I will get it at some point. I would soy it's a 100% 
chance, unless I pass away before I get it ". 
Six of the participants (P2. P5-P7. P8 and P9) incorrectly stated that the genetic test could 
provide information on whether or not a person had cancer or could identity cancer in the 
body. However. all the participants. except for PIO, could correctly explain what type of 
information the genetic test could provide, when they were asked the question relating to 
their understanding of the genetic test as compared to the colonoscopy. When PIO was asked 
about the genetic test she commented: 
"It can tell you if you have cancer or not, and in which part of your body it may be, and if 
they find a growth they must remove it, and the quicker they remove it the better it will be for 
me ... " 
PIO was asked about the colonoscopy and ifboth tests were necessary: 
"It can tell you if there is a gene, or if there is not a gene, and you have to go for the 
operation or you don't have to go for the operation. It can also tell you about the colon of 
the gene itself, if there is a fault in the colon, and as I said, you will have to go for an 
operation or you won't have to ". 
She also added: 
HI can't think there is a difference between the two tests (between the genetic test and the 
colonoscopy), they also went in with the scope at that time ". 
Interestingly. PIO was a nurse and it was surprising to see that she was the participant that 
illustrated the greatest confusion and had difficulty in distinguishing between the genetic test 
and the colonoscopy. 
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Table 4.6: Frequency of responses in each category (n=10). 
10 100% 
7 3 70% 
8 2 80% 
9. Half of your genes are from your mother and the other half 
7 3 70% from father 
10. If a person has the gene. the chance of developing eRe may 
8 2 80% 
be reduced with 
11. you have a healthy lifestyle you are less likely to develop 
7 3 70% eRe 
12. If there is something wrong with your genes you will notice 
9 1 90% 
this will feel a difference in 
MeaD level of knowledge 67% 
The percentage of individuals correctly answering each of the 12 items ranged between 
10% (item 4) and 100% (item 5). The total scores for each participant across the group 
ranged between 50% (6/12) for P8 to 92% (11112) for PlO, with the average total score 
calculated at 67%. Most participants responded correctly to items 5 (100010) and 10 
(80%), which assessed the knowledge on surveillance measures. Items 1 to 4 assessed 
awareness of sporadic eRe and the knowledge of incomplete penetrance of the gene 
mutations, which was answered incorrectly by the majority of participants. Few 
participants knew that there was more than one gene predisposing to eRe. By contrast, 
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4.4.1 Discussion of understanding of predictive test and perceived risk 
4.4.1.1 Reasons/or taking the test 
The findings of this study were similar to those ofClaes et al (2004) and Esplen et al (2001), 
who found key motivation factors to include: early detection of cancer, concern for 
children's risk and reduction of uncertainty. Esplen et al (2001) suggested that pursuing 
testing to gain certainty about the children's risk might be linked to feelings of guilt or 
anticipated feelings associated with passing on the illness to their offspring. 
A desire to further research has also been highlighted in the literature (Esplen et al 2001). 
This may be related to the close relationship with the medical professionals and the 
continuous follow-up and contact, although recommendation by a doctor did not 
significantly increase test uptake. Family and marital planning did not appear to playa major 
role in predictive testing for HNPCC, and may have been related to the fact that for the 
majority, decisions regarding this aspect of their lives had already been made prior to testing. 
4.4.1.2 Level 0/ understanding and perceived risk 
The estimated lifetime risks were assessed and six of the ten individuals underestimated their 
cancer risk as being only 50% or less, which in this context, referred to the very high cancer 
risk without regular surveillance. Aktan-ColJan et al (2001) found the level of 
misunderstanding amongst mutation-positive individuals. to be high, especially among the 
elderly and less educated. In contrast, this study reflected a range, not limited to a specific 
age group or education level, for those individuals underestimating their CRC risk. None of 
the individuals reported a perceived risk at the same level as that communicated to them 
during counselling. This has also been demonstrated by other studies (Domanska et a12007; 
Aktan-Collan et aI2001). 
Possible explanations for the underestimated lifetime risks expressed, may include a 
reflection of a coping mechanism such as denial or risk minimisation. Another consideration 
could be the difficulty in expressing a high but not an inevitable risk in percentages, which 
may result in the simplification of the risk into the possible outcomes - either it will or it 
won't happen. Wei! (2000) states that, when faced with a critical decision about uncertain 
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the subjects had correctly recalled their mutation status, the understanding of the test result 
seemed to be complex. 
A review on risk communication in genetic testing for cancer suggested that the individual's 
perception of the personal risks of cancer, are resistant to education and counselling (Croyle 
and Lerman 1999). Findings by Hopwood et al (1998) have suggested that previous 
experiences of cancer, within the family. shape the individual's belief of how threatening the 
disease is. Additionally, McAllister (2002) found these experiences were used as a reference 
point in interpreting personal risk, in her study of predictive genetic testing. Therefore it is 
likely that the experience and knowledge of hereditary cancer plays an important role in the 
individual's interpretation regarding cancer-risk information provided to them during 
counselling. For 60% (6/10) of the participants in this cohort. family history was noted as art 
additional factor (independent of their actual risk), influencing their perceived cancer risk. 
The majority recalled that affected family members had passed away as a result of CRC, and 
were likely to have built up personal beliefs surrounding this. Many of the participants 
believed the cancer to be inevitable and the illness and or death of other family members 
added to this risk perception. These findings support other studies indicating that lived 
experiences and family history affect how individuals construct perceptions of personal 
cancer risk (d'Agincourt-Canning 2005; McAllister 2002). According to d' Agincourt-
Canning (2005), perceptions of cancer risk depend more on emotional well-being and life 
experiences rather than the numerical risks. This should be an important consideration for 
those involved in managing these individuals, and highlights the significance of probing 
more deeply into the individual's experiential knowledge. 
For PI, an individual with a tertiary level education and a good comprehension of the genetic 
test and results, an 80% lifetime risk was still viewed as a certainty that he would develop 
CRC. PI stated that his experience of his family's HNPCC-related cancer and realisation of a 
personal risk had been at a young age (13 years). In addition to being aware of his family 
history at an early age, he drew on the experiences of affected family members (grandmother 
and his mother) to construct knowledge on the cancer and the course that it may take on his 
own life. Van Oostrom et al (2006) confirms that individuals with an affected parent tend to 
perceive cancer risks as higher than those without, and the highest level of cancer distress 
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4.4.1.3 Cancel' related knowledge 
The average knowledge score among the ten participants was 67%. The knowledge 
scores recorded by other studies in cohorts of individuals at risk for breast cancer 
(Meiser et a12001; Lennan et a11996) and CRC (Collins et a12000) have illustrated an 
increase in knowledge scores post-test counselling as compared to pre-test counselling. 
This study only investigated the HNPCC-related cancer knowledge among the 
participants at one point in time and could not be directly compared. It can be noted that 
the scores reflected a good knowledge of colonoscopic surveillance. but only moderate 
levels of recall about the genetic aspects of colon cancer. The data presented in this study 
showed that the level of knowledge was related to the education level and less 
convincingly to the socioeconomic status. As with other studies. education was found to 
be associated with knowledge score, and a higher education could be assumed to 
facilitate a better understanding (Collins et al 2000). This finding suggests that 
individuals with lower levels of education may benefit from additional counselling to 
improve their genetic knowledge levels. 
4.SIMP ACT OF GENETIC TESTING ON THE INDIVIDUAL 
Participants were asked questions relating to their experience following the test disclosure. 
































Due to the family history of cancer, 
Had expected it, so was 
felt that there was a strong possibility prepared. 
of testing positive. 
Expected to test negative. 
Was uncertain- " 1 was open to 
anything" . 
"I didn't really affect me one way or 
the other". 
Felt certain of testing positive. 
Very upsetting. Having to 
ten the parents was worse for 
her than receiving the 
positive test result. 
Discouraged and sad. Had 
pictured other family 
members who had died as a 
result of the cancer. 
Not too concerned-had a 
positive outlook on life. 
Disappointed and sad. 
Immediately thought of her 
children and worried about 
who would look after them if 
an in ha ed to her. 
Yes - Family is the support 
system for each other. 
Yes - "Can't hide such a thing 
away from your family". Very 
close to her family. 
Yes - Only certain members 
that they were close to. 
Yes - Open family and discuss 
everything. 






























P6 felt that she would test negative. 
"I felt 1 would not be a carrier". 
Suspected that she would test 
positive. 
Knew she would test positive as a 
result of previous health concerns 
(unrelated health problems). 
Had a feeling he would test positive. 
Uncertain. 
"I didn't feel like myself'. Yes - Only with her mother. 
I felt normal- I was the eldest Yes - Only with mother, 
so I knew I had to have if'. husband and aunt. 
Had felt like the end of the Yes - "Shared result with 
world, then realised she had whole family as they have a 
to live with it. Worried and right to know, as they are 
concerned, but accepted it. family". 
Was not good news, but 
Yes - Shared with family and didn't feel bad about it. Had 
a feeling prior to the time, 
friends as felt a sense of relief 
was not stressed or worried. 
by telling them. 
Very emotional. Difficult to 
Yes - Shared with mother and 
understand as had led a 
sister. Felt that if something 
healthy lifestyle. 
were to happen to her, they had 
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P2 and P6 were the only participants who expected to test negative prior to receiving their 
predictive test results. When P2 was asked about how she had felt when a positive test result 
was given, she commented: 
"... it was difficult to hear. What was even more devastating was telling the parents, with a 
father that was sitting there, knowing that he could possibly have given it to his child That 
was the worst" (translated). 
PIO also commented on sensing her mother's guilt when she disclosed the test result to her 
family. Projection describes a defence mechanism whereby a person attributes their own 
unwanted or undesirable emotions onto another person (Weil2000; Djurdjinovik 1998). It is 
possible that feelings relating to the guilt of passing on the condition may be something that 
was projected onto the parent's experience in both these cases. These assumptions may 
reflect the emotions currently being experienced by the participants, relating to their own 
guilt. 
For PS, one of the participants who had felt certain that she would test positive, it was still a 
shock to receive confirmation of an unfavourable result. She had actually hoped that her 
expectation would be proven wrong. When asked how she felt following the outcome, she 
responded as follows: 
HI was very disappointed. Actually I was more saddened. I thought, my gosh, my children 
are still so young, if I had to die, what would happen to them" (translated). 
PIO stated that it had been very emotional for her to receive the result; she had felt that her 
life would end at that moment. She commented: 
"It was very difficult when I heard; I asked them, why ... I don't smoke, I don't drink, why do 
I have it in me then and some of my sisters don't have it. It was a shock, because I make sure 
that I lead a healthy lifestyle, why do I have it? " 
Further comments made by the participant included: 
"Ifelt extremely upset .... I cried and cried ... I asked myself time and time again, I thought, 
my life ends here, but afterwards I sat down and prayed and felt my life would not end here. 
There are so many people with cancer who still live a long life, and if my cancer is so bad, I 
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but if they do find something and I require an operation, will I ever wake up again and those 
thoughts scare me ": 
For PI 0 it was the fear of a future surgery that consumed her thoughts, not only the increased 
risk of cancer. Several times during the interview, she recollected how terrified she was by 
the thought of surgery. 
Nine of the ten participants had shared their test result with their family, or selected family 
members who they were especially close to. The majority stated that they viewed their 
family as a support base and were open about such issues with them as they were close to 
one another. PIO and P7 voiced similar reasons as to why they had shared this with certain of 
their family members. P7 commented: 
"They must know, my mom, my husband and my auntie, because when I die, then they will 
know what caused it "(translated). 
Only P5 had not shared her result with her family. Many of her siblings had passed away and 
of those that were still alive she did not feel close to or that she could trust them. 
In this study. participants were additionally asked a range of questions relating to their 
perception of controllability over developing cancer and subsequent surveillance measures 
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Table 4.8: Perception of the predisposition to cancer (n=10). 
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1 No control unless medical 
solution becomes available in Not relative to specific age Yes 
future 
2 Can lower chance by a "Older you get. greater Yes - "Won't be shocked 
healthy lifestyle risk". In 40s as family got ifI get it" it then 
3 Yes - by going for regular Yes - If develop it will 
check-ups and colonoscopies 30s - family got it then catch it early 
4 Yes - healthy lifestyle. SOs - family developed it Yes - Cope well as has a regular check-ups and pick it around this age lot of support 
up early 
S '" No specific age '" 
6 Yes - with prayer No specific age Yes - Cope through faith 
7 Yes - colonoscopies No specific age Had not thought about it 
8 "I am now 44 and 
Yes - with faith susceptible when you Yes - Has to live with it 
reach that age" 
9 Yes - colonoscopies '" Yes - Prepared himself 
10 No '" '" 
'" Did not know or did not answer the question directly 
The age at which close family members were diagnosed with an HNPCC-related cancer 
acquired particular salience for many of the participants. Four of the participants were 
convinced that if they were to develop cancer it would be near the age of their affected 
family members. P3's comment illustrates that her concern and sense of vulnerability 
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" ... if 1 look at my sister, she developed it when she was very young. She developed it in her 
early 30 's and 1 wonder ... and my dad was in his late 50 's, so why did my dad have it at 50 
and she in her 30 's, and 1 think she had a stressful life and 1 wonder if that is part of it 
happening quicker than .. .! have this in my mind that at 30 1 must really start worrying!" 
P4 felt that the possibility of developing cancer would also be age-related: 
"If it had to occur, probably round about now is when it would happen. 1 tum 50 next year, 
and if it's going to happen it will probably happen within the next few years, as the majority 
of my mother's side of the family developed it roughly between 45 and 50 "{translated}. 
The other participants gave no specific age, while P9 and PIO did not know. 
P7 was the sole participant to state that, if she ever developed cancer, she did not think she 
would survive it. She was extremely afraid and revealed that she had no control over 
preventing it. PI and PIO responded that they had no control over whether or not they would 
develop cancer, however PI did feel he would survive it while PIO did not know if she 
would survive it or not, and was terrified by the thought of cancer. Support from family, faith 
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Table 4.9: Compliance with colonoscopic surveillance fonowing genetic test result (n=10). 
Involved in 




2· 3 67 
3 
No 
1 1 100 
4 
Yes 
6 6 100 
5 
Yes 
2 2 100 
6 
Yes 
2 2 100 
7 
Yes 
2 2 100 
8 
Yes 
3b 4 75 
9 
Yes 
2 2 100 
Involved in 
10 surveillance prior to 6 6 100 
testin 
t Recommended surveillance was calculated for each individual participant. The date of result 
disclosure (according to the genetic test report) and recommended age-related colonoscopic frequency 
was taken into account. 
• Compliance was calculated by dividing the attended nwnber of colonoscopies by the recommended 
nwnber of colonoscopies. a Unable to attend scheduled colonoscopy as a result of an unassociated 
medical complication. bAt the time of the study the scheduled colonoscopy date for the current year 
was still outstanding. 
Eight of the participants had never had a colonoscopy prior to genetic testing. Within the 
year following disclosure. nine of the ten proceeded to have a colonoscopy and the one 
participant who did not. was younger than 25 yeats (colonoscopies not strictly recommended 
before this age). The majority of participants (7110) were adherent to the recommended. 
screening guidelines. except PI, P2 and P8. However PI had been unable to receive a 
colonoscopy as a result of the travelling nature of his job at the time; P2, an unrelated 
medical complication; and P8 was still scheduled to have a colonoscopy (at a stage later than 
the completion of this study). Therefore aU the participants could theoretically be shown to 
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4.5.1 Discussion of the impact of genetic testing on the individual 
4.5.1.1 Satisfaction with the decision 
All the participants were satisfied about their decision to go for predictive testing. They were 
asked to consider whether or not they felt they had made the right decision, and if given the 
opportunity to go back in time, would have made a similar decision. All participants (l0/1O) 
felt they would have retaken the test. Regret of being tested was not expressed by any of the 
participants. Furthermore, they all viewed the genetic test as reliable and trusted the result 
completely. 
4.5.1.2 Psychosocial impact 
One of the main concerns associated with offering predictive testing, is the potentially 
adverse emotional impact on the individual. Counselling is aimed at having a positive impact 
on reducing distress and studies have found the adverse psychological outcome among 
individuals receiving their test results, to be minimal (Claes et a12005; Wagner 2005; Claes 
et aI2004). The literature on the impact of predictive testing and counselling has highlighted 
that depression, anxiety. and cancer worry scores were within normal ranges and there were 
no long-term adverse psychological outcomes (Oritz et al 2005; Meiser et al 2004; Aktan-
Collan et al 2001). Collins et al (2007) confirmed these findings, following assessment of 
these outcomes over a period of three years. The value of this finding has important 
implications for individuals considering predictive testing, as participants can be reassured 
that no adverse psychological outcomes have been observed among those testing mutation-
positive (Meiser et aI2004). 
However, mean results can often obscure the individual reactions (Claes et al 2004) and 
these individual reactions may vary greatly (Chapman and Bum 1999). The use of a 
qualitative format including interviews and open-ended questions was a strength of this 
study, as responses were not limited to psychometric measurements. Questions relating to 
the individual's general distress at the time of result disclosure and concern about the 
prospect of developing cancer were included in the interview. Sixty percent (6/10) of the 
participants expressed emotions relating to shock and distress post-test result disclosure. 
However a general reflection of being able to cope with a cancer predisposition, and survive 
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Open communication among family members is generally associated with more effective 
coping and greater emotional support (Weil2000). For many of the participants, support was 
another essential component of their coping process. Nine of the ten participants 
communicated their mutation status to their family. and expressed this as one of their reasons 
for the disclosure. A further source of support identified by the participants included being 
involved in a predictive testing programme. For P5, the only participant who stated that she 
did not trust her family or communicate with them about the family cancer, this was a central 
source of support. 
4.5.1.3 Cancel' surveillance 
Predictive testing is valuable in the management of HNPCC. as it facilitates targeted 
screening of high-risk individuals (Stanley et a12000; Jarvinen et aI2000). An individual's 
perception of disease may not only have an influence on emotional reactions and coping 
response, but additionally on their health-related behaviour (Leventhal et al 2003). In the 
present study, 70% (7110) of the participants perceived that they had some control over their 
increased risk of CRC, (four out of the seven viewed this as a result of regular screening). As 
suggested by other studies, the focus on the benefits of regular screening probably fosters the 
participant's ability to cope with the genetic test result and predisposition to CRC (Keller et 
al 2002; McAllister 2002). This is further supported by the overwhelming confidence 
illustrated by the participants in the effectiveness of the surveillance programme. All (1011 0) 
of the participants believed the colonoscopy was capable of detecting CRC and eight of the 
ten, believed that it could reduce their chance of CRC (Table 4.6, page 45). 
An important finding ofthis study was the high compliance rate (7/l 0 participants adhered to 
surveillance recommendations and 10110 were involved in colonoscopic screening 
practices). Noteworthy, is the fact that this held true for individual's representative of poor 
education levels, low socio-economic status, those underestimating CRC risk and individuals 
with a poor understanding of the genetic test and implications thereof. However, these 
individuals are faced with the necessity of adherence to this health-related behaviour for a 
long period of time. Long-term follow-up of the cancer screening in these individuals will be 
needed to see whether the high uptake remains. This was also a recommendation arising 
from Kruger's (2005) work. She investigated the factors affecting non-adherence and 
adherence to surveillance guidelines for mutation-positive individuals in rural areas of the 
Northern and Western Cape Provinces in SA. 





















CHAPTER 5: CONCLUSION 
CHAPTER FIVE 
5.1 CONCLUSION 
One of the central features of genetic counselling is to enable the comprehension of an 
individual's risk for a disorder and facilitate the understanding of options for dealing with 
this risk (Resta et a12006; Weil2000). In the context ofHNPCC, genetic counselling can be 
considered effective if it results in an improved accuracy of perceived risk, knowledge of the 
disease, genetics and adherence to recommended screening, without causing undue anxiety 
(Braithwaite et aI2006). 
The main aim of this study was to provide insight into the level of understanding of the 
individual's genetic predisposition to CRC, following predictive testing for HNPCC. This 
included investigating the subsequent impact on the individual, specifically in terms of: the 
risk perception, psychological effect and ad~erence to screening recommendations. The use 
of qualitative in-depth interviews allowed the participants to discuss their beliefs and 
emotions, relating to their experience of the predictive testing, in a way that quantitative 
research could not. Such an insider's view, obtained through the use of personal interviews 
with the participants, was suited to the provision of information on the understanding and 
impact of the predictive test result. 
Predictive testing has far-reaching implications, not only for the individual but also for the 
rest of the family (Evers-Kierbooms et al 2000). This was particularly evident, as one of the 
main motivations for the uptake of the predictive test, among the participants, was to obtain 
knowledge of their children's risks. Additionally, the experience of an HNPCC-related 
cancer in the participant's family appeared to have a significant role in the individual's 
interpretation of information. The emotional representation of the disease, influenced by the 
individual's personal experience and perceptions of cancer in the family, rather than the 
given information seemed to affect the perceived risk of the participants. 
Further findings of this study indicate that the majority of individuals illustrated a 
misunderstanding of their CRC risk, particularly an underestimation. However, the perceived 
risk among the individuals was high and some viewed the possibility of developing an 
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provided and perceived risk, most likely reflects the process of binary reasoning. As 
participants were already involved in the screening programme, a further consideration could 
be linked to the high efficacy of the colonoscopy in terms ofCRC prevention. Noteworthy, is 
the fact that none of the individuals involved in the study reported a perceived risk at the 
same level as that communicated to them during counselling. Therefore attributing a great 
deal of time and effort into providing accurate risk figures may be time misspent (Mackay 
and Ponder 1997). 
Perceptions of perceived risk have previously been suggested to be relatively resistant to 
educational efforts (Croyle and Lerman 1999) and largely been shown to be unique to each 
individual. Risk comprehension among participants is critical to decision-making about risk 
management. Incorrect perception is acceptable, as long as these individuals continue to 
participate in the screening programmes; and are aware of the reason for the prevention 
procedure. 
As predictive testing can have an impact not only on health-related behaviour but also on 
distress levels (Claes et al 2005), this aspect was additionally investigated. The small sample 
in this study did not reveal any significant psychological problems as a consequence of the 
predictive test result. However, the interview data indicated some individually different 
problems in addition to the concern over being at an increased risk, such as the fear of the 
possibility of future surgery. 
It is not easy to convey the information that predictive testing represents in a way that 
facilitates the recipient's understanding and relevance thereof. While such testing has 
considerable potential for accurate risk assessment and appropriate targeting of screening 
and preventative strategies, it remains at best, predictive. This study suggests that a good 
level of understanding and knowledge related to hereditary cancer can be demonstrated for 
the majority of the participants (mean level of knowledge of the ten participants was 67%). 
Particularly evident was the insight of how to prevent CRC and the effectiveness of 
colonoscopies. This may be associated with the high adherence rate to screening 
recommendations. 
It is important to realise that the time following result disclosure varied across the sample (a 
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may have influenced the level of knowledge and understanding. While this should be 
interpreted with caution, it does support the importance of having a person trained in dealing 
with genetic information as part of the clinical team. Furthermore, it could reflect the 
benefits of such constant revisiting of information. This however, did not appear to influence 
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CHAPTER SIX 
6.1 RECOMMENDATIONS 
6.1.1 Recommendations identified through the study: 
The small sample size of only ten individuals is a major limitation and the results reflect very 
individualised experiences, which cannot be generalised. However the study provides a 
useful framework for further research, together with potential implications for genetic 
counselling in the predictive testing programme. Recommendations obtained from the 
findings include: 
• Many of the participants believed the HNPCC-related cancer to be inevitable and the 
sensitivity of this response should strengthen the argument for continued support to 
these individuals; 
• Vulnerable individuals may include those participants with a parental cancer 
diagnosed during their childhood and the highest levels of anxiety could be 
suggested to occur at a time nearing the age of the affected parent's diagnosis. An 
effort should be made to identify subjects where this may be the case, and 
psychological support should be more actively offered. As family history plays such 
an important role in risk perception it may be a useful tool in enabling identification 
of individuals at risk for adverse psychological consequences; 
• A deeper exploration into the personal experience of cancer in relatives. To 
understand the perspective and background of the individual participant, 
investigation into how the cancer is represented in the individual's mind and the 
related anxiety and concern, may be required. Beliefs and attitudes may not simply 
be corrected through the provision of facts alone. and educational approaches may 
not be enough to correct misperceptions. d' Agincourt-Canning (2005) suggests that 
counselling strategies, which expand upon the lived experiences and knowledge of 
the disease may enhance effective communication of genetic risk. 
6.1.2 Recommendations from the participant's perspective: 
At the end of each interview. the participants were given the opportunity to comment on or 
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participant's experience of the counselling received during the programme was especially 
positive. Regular follow-up in terms of reminders to attend screening practices and a support 
system was highlighted by the participants. Further recommendations from the participants 
included: 
.. The provision of more written material with the focus on practical issues specifically 
how to live a healthy lifestyle; 
.. To be informed of emerging therapies and treatment options and to receive feedback 
on future research; 
.. More aggressive pursuit of family members who were not adherent to screening 
recommendations (although this may be controversial to apply and unethical). 
6.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
It will be of value to consider the following suggested projects: 
.. The study focused on individuals who had already received their test results, and 
their interpretation may have been subjected to potential recall bias and influenced 
by the knowledge of their test result. A prospective study design, with a larger 
sample number and assessment over a number of time points could be beneficial in 
further exploration of these preliminary fmdings; 
.. Include participants representative of the rest of SA. This study only investigated 
individuals from urban areas and experiences from rural areas would be required for 
comparison purposes; 
.. The underestimation of the HNPCC-related CRC risk did not influence screening 
behaviour negatively, however there is a need for further follow-up of screening 
behaviour over the long-term, given its role in CRC prevention; 
.. The impact of previous experiences of cancer in the family appears to be an 
important moderating factor that needs a greater consideration in future 
investigations; 
48 The family are often the messengers of information relating to predictive testing. 
Two of the participants received such information from their family prior to any 
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M.Sc in Genetic Counselling Research Project 
HEREDITARY NONPOLYPOSIS COLORECTAL CANCER: COMPREHENSION OF A 
. CANCER RISK IN CONJUNCTION WITH A GENETIC RISK. 
INFORMATION AND CONSENT FORM 
STATEMENT BY PARTICIPANT 
I, ......................................................................... Living at (address) 
confinn that: 
1. I have been invited to participate in the above research project. which has been 
initiated through the Division of Human Genetics, University of Cape Town because 
I have received my predictive genetic test results and am currently involved in the 
HNPCC predictive testing programme. 
2.1 I understand that the objective of this study is to investigate: 
• the level of understanding of a genetic predisposition to cancer following predictive 
testing for HNPCC; 
• the subsequent impact on the individual. 
2.2 I understand that the interview will take place in my home or at another venue of my 
choice and that it may take one or two visits of up to two hours each. 
2.3 I am aware that this is a once off procedure that will be implemented in 2007 at a 
time convenient to me. 
2.4 I understand that some of the questions may make me angry or sad, but the risks to 
me from the study are minimal. The researcher will refer me to a genetic counsellor if 
necessary. She will show me respect, acceptance and empathy during the interview. 
3.1 I have been assured that all the infonnation will be handled confidentially. 
Infonnation may be used for a thesis, publications in scientific journals and at 
presentations at professional congresses, but names will not be included. 
3.2 I understand that the interview will be tape recorded so that the researcher does not 
have to write too much during the interview. The tape will be stored in a safe place until 
the research has been written up and will then be destroyed immediately. The data stored 
on the computer will have a numerical code only and my name does not appear 
anywhere. . 
4.1 I have been assured that the recorded and transcribed infonnation discussed at the 
meeting will only be made available to the researcher's supervisors with my study code 












5. I have not been persuaded to consent to taking part in the study and I have been 
informed that I my refuse to participate in this project, that I may stop participating at 
any stage, and that such refusal or stoppage will not in any way negatively affect my 
future access to medical and genetic services to which I am entitled. 
6. ........................................ has explained the information of the study to me in 
English! Afrikaans. I am proficient in that language and my questions have been 
answered satisfactorily. 
7. I understand that there will be no medical benefits to me from this study. 
8. I have been assured that participation in this project will not lead to additional costs 
for me and I will not benefit from it financially. 
I hereby declare that I voluntarily agree to participate in the above research 
study 
Signed at: 
(address) ............................................ .. on ........ .1 ....... .12007 
Participant's signature Witness 
I hereby declare that I agree to have my interview audiotape recorded 
Signed at: 
(address) ............................................. . on ........ .1 ....... .12007 














Thank-you very much for your participation in this study. If you have any questions about 
"the research concerning: 
1. problems due to the research. or 
2. questions relating to the infonnation about the project 
you can contact me or Prof. Greenberg on: 
Zandre Brower (021) 406 6373 
E-mail: zbrower@connack.uct.ac.za 
Prof Jacquie Greenberg (021) 406 6299 
If you have any questions relating to your right as a participant, contact Prof. Marc 













M.Sc in Genetiese Berading Navoningsprojek 
HEREDITARY NONPOL YPOSIS COLORECTAL CANCER: COMPREHENSION OF A CANCER 
RISK IN CONJUNCTION WITH A GENETIC RISK. 
INLIGTING EN TOE STEMMING VORM 
VERKLAARING DEUR DEELNEMER 
Ek, ............................................................... , 
(adres) ......................................................... . 
bevestig dat: 
1. Ek is uitgenooi om aan die bogenoemde navorsings projek wat deur die Divisie van 
Mensgenetika, Universiteit van Kaapstad geinisieer is, deel te neem aangesien ek my 
voorspellings toets resultate ontvang het en tydens betrokke is in die HNPCC 
voorspeHings toets program. 
2.1. Ek verstaan die doel van hierdie projek is om die volgende te ondersoek: 
• Hoe 'n persoon die voorspellings toets resultate verstaan en; 
• die impak daarvan op die individie; 
2.2. Ek verstaan dat die onderhoud of by my huis of by 'n ander plek van my keuse 
sal plaasvind en dat dit een of twee besoeke van twee ure elk behels. 
2.3. Ek is bewus dat dit 'n eenmalige ondersoek is wat in 2007 sal plaasvind op 
'n tyd wat vir my en my gesin gerieflik is. 
2.4. Ek verstaan dat van die vra my hartseer of ongelukkig mag maak, maar dat die 
risiko's van die studie minimaal is. Die navorser sal my na 'n genetiese 
raadgewer verwys indien nodig. Sy sal my met respek, aanvaarding en empatie 
behandel geduurende die onderhoud. 
3.1. Ek is verseker dat aIle inligting vertroulik behandel sal word. Inligting mag vir 
'n tesis, publikasies in wetenskaplike tydskrifte en aanbiedings by professionele 












3.2. Ek verstaan dat die ondemoud op band opgeneem sal word sodat die navorser 
nie te veel hoef te skryf geduurende die onderhoud nie. Die band sal in 'n kluis 
gestoor word tot dat die navorsing opgeskryf is en sal daarna dadelik vemietig 
word. Die band en die data op die rekenaar sal slegs 'n numeriese kode op he en 
my naam sal nie daarop verskyn nie. 
4. Ek is verseker dat die inligting wat opgeneem en getranskribeer is slegs aan die 
navorser se mentor bekend gemaak sal word, maar dit sal slegs my numeriese 
studie kode bevat en my naam sal nie daarop verskyn nie. 
5. Ek is nie oorreed om aan die die projek deel te neem nie en ek is bewus dat ek mag 
weier om deel te neem, en ek kan op enige staduim besluit om te onttrek. My 
onttrekking salop geen manier my huidige of toekomstige toegang tot die mediese 
of genetiese dienste, waarop ek geregtig, is beYnvloed nie. 
6 .............................................. het die inligting van die projek in 
Engels/Afrikaans aan my verduidelik. Ek is vlot is hierdie taal en my vra is 
ten volle beantwoord. 
7. Ek verstaan dat daar geen mediese voordele vir my sal wees as gevolg van hierdie 
projeknie. 
8. Ek is verseker dat my deelname aan hierdie projek nie tot enige additionele koste 
vir my familie sal lei nie en dat ek nie finansieel gaan baat daarby nie. 
EK VERKLAAR BlERMEE DAT EK VRYWILLIG AAN DIE BOGENOEMDE 
NAVORSINGS PROJEK DEELNEEM 
Geteken te: 
(Adres) ............................................... op ., ................................. 2007 











EK VERKLAAR HIERMEE DAT EK MY ONDERHOUD OP BAND OPGENEEM 
MAG WORD 
Geteken te: 
(Adres) .............................................. op ....................................... 2007 
Deelnemer se handtekening Getuie 
BELANRIKE INLIGTING 
Geagte deelnemer. 
Baie dankie vir u deelname aan hierdie studie. As U geduurende die verloop van die 
navorsing enige vra het aangande: 
1. probleme as gevolg van die navorsing. of 
2. vrae aangaande inHgting oor die projek 
kontak my of Prof. Greenberg gems op die volgende telefoon nommers: 
Zandre Bmwer (021) 406-6373 
Email: zbmwer@cormack.uct.ac.m 
Prof Jacquie Greenberg: (021) 406-6299 
As u enige vrae het in verband met u reg as 'n deelnemer, kontak Prof. Marc 
Blockman, die Voorsitter van die Etiese Hersiening Komitee van die Universiteit van 













INTERVIEW SCHEDULE .. English venion 
Participant number: 0 0 
Section A: Assessment and update of pedigree information 
The pedigree together with section A will be used in answering the following questions: 
Is all the information on the pedigree still correct? 
1. Do you have any children of your own (blood relatives)? 
o No 
DYes 
If yes please indicate the gender and age 
1st Child: Age: 
Boy? ·0 
Girl? 0 
2nd Child: Age: 
Boy? 0 
Girl? 0 
3rd Child: Age: 
Boy? 0 
Girl? 0 
4th Child: Age: 
Boy? 0 
Girl? 0 
2. How many brothers do you have? 
3. How many sisters do you have? 











s. How many of your sisters have had cancer? (who you are aware of) 
6. To your knowledge have any of your brothers passed away from cancer? 
7. To your knowledge have any of your sisten passed away from cancer? 




9. When was the first time that you realised that cancer was in your family (how old 
were you)? 
10. How old were you when you realised you were at risk for colon eaneer (had a 
chance of developing the colon cancer)? 
11. When was your fint recruitment session (information and blood taking session) 
with the genetic team? 
12. Has your blood been tested for the gene that causes colon cancer in 
your family? 
DYes 
o No (go to question 14) 
o I don't know (go to question 14) 
IF YES TO QUESTION 12 - When did you receive your result for this genetic test? 
13. Do you have the gene that causes colon cancer in your family? 
DYes 
o No (go to question 15) 
o I don't know (go to question 15) 
14. IF NO OR I DON'T KNOW TO QUESTION 12: The researcher will explain that the 
participant did have the test at a certain date and explore their reasons for not understanding 
this. The genetic status will be discussed with the individual in a supportive way. 
15. IF NO OR I DON'T KNOW TO QUESTION 13: The researcher will explore the 
participants reasoning for their answer. The researcher will infonn the participant of their 
genetic status in a supportive manner. 












16. Can you recall who gave you this result? 
17. Where was this result given to you? 
18. Do you remember the day tllat you received this genetic test result? Can you recall 
it in much detail? 
Section B: Sociodemographic Information 
19. What is your date of birth? 
[JJ Day CD month ..... 1 -'--''--'-...... year 
20. Are you male or female? 
o 
Male o Female 
21. Until which grade/standard did yon complete school? 
o 
Grade 12 (matrie/standard 10) 
0 Grade 11 (standard 9) 
0 Grade 10 (standard 8) 
0 Grade 9 (standard 7) 
0 Grade 8 (standard 6) 
0 Grade 7 (standard 5) 
0 Other - please provide standard/grade 
22. Did you have biology at school? 
o o 
Yes No 
If yes, until whieh grade/standard? ............................................. . 
If yes. how do you rate your knowledge? ...................................... . 
















D Discuss with family members 
D Other 
24. What is the highest level of education you have obtained since leaving school? 
Please indicate the specific type if relevant. 
D No post-school 
D Tradel Apprentice 
D Certificate from college 
D Diploma (beyond standard 10) 
D Bachelors degree 
D Postgraduate degree I degree 
D Other ................................................. . 
25. Do you belong to a specific religious denomination? 
26. IIu your religion played a major role in copiug with your genetic test results? 
Many facton influence the way we live our life. What would you consider is the most 
important factor that guides your life and helps you make decisious? 
27. Do you work? 
D D 
Yes No 
If yes to the question, what kind of work do you do? 
hthework; 
o Self-employed 
o Full-time employed 
o Part-time employed! Casual 
If no to the question, are you: 
o Unemployed 
o Permanently unable to work 













28. Bow many people live witb you iu tbe bouse wbere you stay? Are tbey all blood 
relatives? 
29. Do you talk to tbem about tbe colon cancel' tbat occun in tbe family? Is tbere any 
particular penon witb whom you talk more frequently? 
30. What is your current household income per month? 
[J No income 
[J Disability grant (what type ........... . 
[J Rl- R400 
[J R401 - R800 
[J R801 - R1600 
[J R1601 - R3200 
[J R3201- R6400 
[J R6401 - R12 800 
[J R12 801 - R25 600 
[J R25 601 - R51 200 
[J R52 201- RI02 400 
[J R102 401 - R204 800 
[J More than R 204 801 
31. Bow many people contribute to the household income? 
32. Bow many people are dependent on tbese incomes? 
33. What is your present marital status? 
o Married! Partner o Single 
o SeparatedlDivorced o Widowed 
o Never married 
how much R ...... ) 























Colon cancer is always inherited - if a person 
develops colon cancer, they always have a family 
history of colon cancer 
Everyone who has the gene causing colon cancer 
will develop colon cancer 
A person who does not have the gene for colon 
cancer is less likely to develop cancer than 
someone with the gene 
There is more than one gene that can cause colon 
cancer 
Colonoscopy (the inside ofthe bowel is viewed 
with a special tube) is very likely to detect colon 
cancer if it is present 
Faecal occult blood testing (a test which tests for 
blood in the stool) is very likely to detect bowel 
cancer if it ispresent 
In a family where the gene causing colon cancer 
has been found, those WITHOUT the gene have 
the same risk for getting colon cancer as the 
general population 
If a person looks like (or has the same personality) 
a family member who developed cancer, they are 
likely to have inherited the same gene as that 
person 
35. Please mark each qnestion as being troe or false 
True False Don't 
Know 
• The increased risk of cancer can be passed on to your children D D 0 
• Everyone with the gene causing colon cancer, will develop colon cancf.J D D 
• 50% of a persons genes are the same as the genes of their 
parents D D D 
• If a person has the gene causing colon cancer, the chance of developing 
the cancer that other family members may have D D D 
can be reduced with regular check ups (colonoscopy) 












• If there is something wrong with your genes then you will notice 
this (you will feel a difference in your body) D 
36. Which of the following may influence whether a person gets cancer? 
No Influence A little A lot of 
Influence influence 
Personality D D D 
Stress D D D 
Environmental pollution D D D 
The gene D D D 
Lifestyle or habits D D D 
Bad luck D D D 










37. Who provided you with the information that a genetic test was available, to test for 
the gene that causes an increased risk for colon cancer? (Nurse! family member) 
38. Whose idea was it for you to have a genetic test? 
o My own idea 
o Other family member 
o General practitioner 
o Specialist 
o Family bowel clinic 
o Other ________ _ 
39. Can this genetic test tell you if you have the gene that may cause you to have an 
increased chance of developing the colon cancer? 
40. Can this genetic test tell you if you have cancer or not? 
41. How is this predictive test done? 
o Physical examination 
o Blood test to identify the gene 
o Colonoscopy 
42. How long has it been since you have received your genetic test results? 
43. When you went for your genetic test, did you think you would test positive for the 













44. Describe how you feel about the fact that the test showed that you have the gene 
causing you to have an increased risk for cancer? 
45. What happened to these feelings or emotioM since the test results? 
46. Have you shared this test result with anyone? 
o No 
o Yes (whom?) 
47. When did you share the result (How long after you received the test result)? 
48. Why did you share this result with them? 
49. How have they responded to you sharing this information (their reaction)? 
50. Explain how the result hu affected your life medically 
51. When last has someone from the genetic team spoken to y u? What was it about? 




o Few times 
o None 
Section E: Recall of cancer risk and subjective risk perception 
53. Do YOU think you are at an increased risk for colon cancer? (reuons besides the 
test) 
54. What is your risk (chance) of developing colon cancer after the genetic testing? 
o I am at 80% risk of developing colon cancer 
o I am at 50% risk of developing colon cancer 
o I have been told that I have colon cancer (100% risk) 
o I am at less than 50% risk of developing colon cancer 
o I am at no risk 
55. Do you think yon have control over your risk of developing colon cancer? 
56. How will you try and prevent the cancer from developing? 
57. Are you worried about your risk (the chance) of developing colorectal cancer? 
[J Very worried 












[J Not at all worried 
58. Have YOII thollght abollt how YOII will cope if yo II develop cancer? 
59.lfyoll were to develop colon cancel', do YOII think that it would develop at a specific 
age? 
If yes, why then ............................... . 
60. Do you trunk the chance that you will develop cancel' is bigger or smaller in 
comparison with someone else of the same age and same sex (not from your family)? 
61. Please rate your chances of getting colon cancer on a scale from 0 to 100, where 0 = a 
0% or no chance and 100 = a 100% chance, meaning that you will definitely get it. 
0% 
.. 
Please make a mark on one of the vertical lines to indicate your chances, given 
your current situation. In your opinion, what number from 0 to 100 reOects your 
chances of getting bowel cancer? 
I I 
10 20 30 40 50 60 70 80 90 100% 
Section F: Motivations for participating in a predictive testing programme 
Please select the most appropriate answer to 
62. Md· . I eclSlon to ave alene c test was III uenc ,ywan ti '0 edb ti III ........................ 




~ 8 c;Q.. CI'.l > Z~ 
To learn about my children's risk 
To reduce my risk of develo~in~ cancer 
To plan for the future 
To help research 
To be certain about my risk 
To make decisions about having children 
Marital decisions 
Doctor recommended it 
Family members urged me to take test 
Worried about abnonnal stoolslhealth related 
concerns 












63. Try to remember the situation when you made your decision about the test. Were 
there any other facton that caused you to take the test? 
64. Why did you not want to take the test? 
65. Are you satisfied with your decision to take the test? 
66. How reliable do you think the test is? 
67. Now that you know the result, would you have taken the test in the fint place? 
Section G: Health-related behaviour 
68. Which day hospital do you go to when you feel sick? 
69. Which hospital do you go to if your health worries relate to your concerns of 
developing colon cancer? 
70. Do you have a medical aid? 
DYes 
DNo 
71. Have you ever had a colonoseopy? 
D Yes (How many?) 
D No 
D I don't know 
72. When was your last colonoseopy? 
73. What can a colonoscopy teU you? 
74. What is the difference between a colonoseopy and a predictive test? 
75. Why do you need both of these tests? 











77. Did you have a genetic test prior to the colonoscopy? 
DYes 
o No 




Section H: Perceived severity (adapted from Aktan-Collan 200n 
79. If you developed colon cancer, do you think you would survive it? 
80. Are you afraid that you may have cancer? 
81. What does your future look like? 
Section I: Opinions of counselling 
82. What is your general opinion about the counselling protocol? 




o Not at aU 
84. Have you had post test counselling? 
DYes 
o No 
85. Do you have any further comments or suggestions? 
The researcher thanks the participant for their time in allowing her to do the interview. 
Support and educational input requiring re-counselling will be offered if emotional concerns 












ONDERHOUD SKEDULE - Afrikaans wergawe 
Ondernemer nom mer: 00 
Seksie A: Familie geskiedenis 
Die familie geskeidenis en seksie A se antwoorde sal gebruik word om die volgende vra te 
beantwoord: 
1. Het u enige kinders? 
o Ja 
o Nee 
Iste kind: Ouderdom: 
Seun? 0 
Dogter? 0 
2de kind: Ouderdom: 
Seun? 0 
Dogter? 0 
3de kind: Ouderdom: 
Seun? 0 
Dogter? 0 




2. Hoeveel broers bet u? 
3. Hoeveel sisters bet u? 
4. Hoeveel van u broers bet al kanker gebad? (Wat u van weet) 












6. Sover u weet, hoeveel van u broers het gesten van dikderm bnker? 
7. Sover u weet, hoeveel van u sisters het gesten van dikderm bnker? 
8. Het een van u ouers bnker gehad ? 
o Ja 
o Nee 
9. Wanneer het u vir die eerste keel' bewus geword daarvan dat dikderm bnker in die 
familie is (hoe oud was u)1 
10. Hoe oud was u toe u agterkom dat u 'n risiko het vir dikderm bnker (bns het om 
dikderm bnker te ontwikkel)? 
11. Wanneer was u eerste sessie (inligting en bloed neem) met die genetiese span? 
12. Is u blood al getoets vir die geen wat dikderm bnker in u familie veroorsaak? 
o Ja 
o Nee (gam na vraag 14 toe) 
o Ek weet nie (gam na vraag 14 toe) 
INDIEN JA NA VRAAG 12 - Wanneer het u die resultate gekry? 
13. Het u die geen wat dikderm bnker veroorsaak in u familie? 
o Ja 
o Nee (gam na vraag 15 toe) 
o Ek weet nie (gam na vraag 15 toe) 
14. lNDIEN NEE OF EK WEET NIE VIR VRAAG 12: Die navorser sal verduidelik dat die 
deelnemer reeds getoets is en sal die redes verduidelik waarom hy/sy dit nie verstaan nie. Dit 
salop 'n ondersteunende wyse gedoen word. Die navorser sal die deelnemer verder op 'n 
ondersteunende wyse intig oor sylhaar genetiese status. 
lS.lNDIEN NEE OF EK WEET NIE VIR VRAAG 13: Die navorser sal die rede 
verduidelik waarom die deelnemer die antwoord gegee het. Die navorser sal die deelnemer 
verder op 'n ondersteunende wyse intig oor sylhaar genetiese status. 
Die navorser sal die deelnemer verwys vir genetiese berading na die onderhoud 
16. Wie het vir u jou resultate gegee (persoon)? 












18. IUn jy die dag goed onthoo? En beskryf'! 
Afdeling B: Sosiooemografiese Inligting 
19. Wat is 0 geboortedatom? 
[I] Dag [I] maandl I jaar 
20. Is 0 manlik of vroolik? 
o 
Man o Vrou 
21. Wat is die hoogste graadlstanderd wat u op skool voltooi het? 
o Graad 12 (matrieklstanderd 10) 
o Graad 11 (standerd 9) 
o Graad 10 (standerd 8) 
o Graad 9 (standerd 7) 
o Graad 8 (standerd 6) 
o Graad 7 (standerd 5) . 
DAnder - dui asseblief aan .................................. . 
22. Het 0 bioiogie op skool gehad? 
o o 
Ja Nee 
Indien ja, tot watter standerd ............................................ .. 
Indienja, hoe beskouujou kennis daarvan? ...................................... . 
















o Bespreek met ander fsmilie lede 
DAnder 
24. Wat is die hoogste kwalifikasie wat u na skool gekry het? 
o Geen o Diploma (na Graad 12) 
o Ambag o Bacculureurs graad 
o KoUege sertifikaat o Na-graadse diploma! - graad 
DAnder ................................................ .. 
25. Behoort u aan enige godsdiens verband? 
26. Speel u geloof 'n groot rol in die manier waarop u, u toets resultate hanteer? 
Baie faktore beinvloed die manier waarop ons ons lewe lei? Wat beskou u as die faktor 




Indien ja, watter tipe werk? 
Is diewerk; 
o U eie besigheid 
o Voltydse werk 
o Deeltydse werk 
Indien nee, is u: 
o Werkloos 
o Kan permanent nie werk nie 













28. Is al die mense wat saam met jou bly in die huis bloedfamilie? Hoeveel mense bly in 
die huis? 
29. Praat julie oor die familie siekte (kanker) met mekaar? Is dan iemand wat jy meer 
gereeld mee praat? 
30. Wat is u huidige huishoudelike inkomste per maand? 
o Geen inkomste 
o Ongeskikheids toelaag (Tipe ........... . bOOmg R ...... ) 
o RI-R400 
o R401- R800 
o R801 - R1600 
o R1601 - R3200 
o R3201- R6400 
o R6401 - R12 800 
o R12 801 - R25 600 
o R25 601 - R51 200 
o R52 201 - RI02 400 
o R102 401 - R204 800 
o Meer as R 204801 
31. Hoeveel mense dra by tot die huishoudelike inkomste? 
32. Hoeveel mense is afhanklik op hierdie inkomste? 
33. Is u getroud? 
o Getroud/woon saam o Enkellopend 
o Geskei o Weduwee/wewenaar 












Seksie C: Kennis 001' bnker (Aangepas van CoUins et al 2000a en De Vries et a12004) 






Dikdenn kanker is altyd oorerflik-daar moet 'n 
fsmilie geskeidenis van kanker wees vir die 
persoon om kanker te ontwikkel 
Almal wat 'n geen het vir oorerflike dikdenn 
kanker sal dikdenn kanker k.ry 
'n Persoon wat NIB die geen vir dikdenn kanker 
het nie, het 'n kleiner kans om kanker te 
ontwikkel as iemand met die 2een 
Daar is meer as een geen wat dikdenn kanker 
veroorsaak 
Kolonoskopie (kyk na die binnekant van die derm 
met 'n spesiale buis) sal heel moontelik dikdenn 
kanker optel as dit teenwoordig is 
'n Okkulteblood-stoolgangtoots ('n toots wat 
onsigbare blood in die stoelgang aandui) sal heel 
moontelik dikdenn kanker optel as dit 
teenwoordi2 is 
In 'n fsmilie waar die geen vir o rerflike dikdenn 
kanker gevind is, het die mense SONDER die 
geen dieselfde risiko om dikdenn kanker te 
ontwikkel as die algemene populasie 
As 'n persoon soos 'n fsmilie lid wat dikdenn 
kanker gehad het lyk (of dieselfde tipe 
persoonlikheid het) het hulle moontelik dieselfde 
2een as daardie persoon 
35. Merk asseblil'f die vraag as waar of onwur Wur Onwur Weet 
Nil' 
., Die verhoogde risiko vir kanker kan oorgedra word tot u kinders 0 0 0 
., Almal wat die dikdenn geen het, sal dikderm kanker 
ontwikkel 0 0 0 
., As a seun soos sy pa lyk, is dit moontelik dat hy dieselfde 
siekte/toostand as sy pa sal ontwikkel 0 0 0 
., 50% van 'n persoon se gene is dieselfde as hulle 
ouers se gene 0 0 0 












kans te verminder met gereelde ondersoeke (kolonoskopie) 
• As jy 'n gesonde lewe lui. is die bns minder dat jy 
oorerflike kanker sal ontwikkel 
• As daar iets verkeerd is met jou gene sal jy dit kan agterkom 
(jy sal 'n verskil veel injou liggaam) 
o o 
o o 
36. Watter van die volgende mag dalk beinvloed of 'n persoon bnker ontwikkel of 
nie? 
Geen invleed Klein Baie Weet nie 
Invloed Invloed 
Persoonlikheid 0 0 0 0 
Stress 0 0 0 0 
Omgevings besoedeling 0 0 0 0 
Die gene 0 0 0 0 
Lewenstyl of gewoontes 0 0 0 0 
Ongeluk (Bad luck) 0 0 0 0 
Seksie D: BegriO van genetiese toea vir dikderm bnker 
37.Wie bet vir u ingelig 001' die feit dat 'n bleed toea vir die geen wat dikderm bnker 
veroorsaak beskikbaar is? (Het een van die sisters of fsmilie lede vir jou ingelig)? 
38. Wie se idea was dit dat u getoets moet word (bleedtoetslgenetiese toets)? 
D Myeie 
D Ander familie lid 
D Dokter 
D Spesialis 
D Familie dikderm kliniek 
D Ander ________ _ 
39. Kan bierdie genetiese toea vir u se of u die geen dra wat veroorsaak dat u 'n 
verhoogte risiko vir dikderm bnke .. het? 
40. Kan hierdie genetiese toea vir bnke .. toea? 
41. Hoe is bierdie voorspeUings toets vir HNPCC gedoen? 
o Ondersoek 
o Blood toets vir die geen 
o Kolonoskopie 














43. Toe u vir die genetiese toets gegaan het, het u gedink u sal positief toets vir die geen 
(voor die resnltate gegee is)? 
44. Kan u vir my beskryf hoe u voel 001' die feit dat u die geen het wat vir 'n mens 'n 
verhoogde risiko vir dikderm bnker gee? 
45. Wat het gebeur met hierdie gevoelings of emosies sedert u die resultut gekry het? 
46. Het u die resultaat met euige iemand gedeel? 
o Nee 
o Ja (met wie?) 
47. Wanneer het u die resultaat met hulle gedeel (Hoe lank na u die resultnt gekry 
het)? 
48. Wat was u rede dat u die resultaat met hulle gedee. het? 
49. Hoe het hulle gereageer op hierdie inligting (hulle reaksie)? 
50. Verduidelik hoe die resultaat u lewe beinvloed het op n mediese vlak? 
51. Wanneer laas het iemand van die genetiese span met u gepraat? Waaroor was dit? 
52. Hoeveel kontak het u al gehad met die genetieselkliniese span na dat u die resultate 
ontvang het? 




Seksie E: Delrip van bnker risiko en bnker persepsie 
53. Dink u, u het 'n verboogde risiko vir dikderm bnker? (enige redes behalwe die 
toets resultate) 
54. Wat is u risiko om dik4erm bnker te ontwikkel na die toetsing? 
o Ek het 'n 80% risiko om dikderm kanker te ontwikkei 
o Ek het 'n 50% risiko om dikderm kanker te ontwikkel 
o Oit is vir my gese dat ek dikderm kanker het (100% risk) 
o Ek het 'n miner as 50% kans om dikderm kanker te ontwikkel 
o Ek het geen risiko nie 
55. Diuk u, u het bebeer 001' die bns om dikderm bnker te outwikkel? 












57. Is u bekommered oor u huidige risiko om dikderm bnker te ontwikkel? 
o Daie bekommered 
o Eft'ens bekommered 
o Glad nie bekommered 
58. Het u aI gedink hoe u die situasie sal hanteer as u bnker ontwikkel? 
59. As u dikderm bnker sou ontwikkel, dink u dit sou op 'n spesifike ouderdom 
gebeur? 
As ja, hoekom dan •• 0 0 0 00 0 00 0.0 •• 
60. Dink u die bns dat u dikderm bnker ontwikkel is grooter of kleiner as iemand 
van dieselfde geslag en ouderdom (nie van joufamilie nie)? 
61. Dui asseblief u kans om dermkanker te lay aan op 'n slmal van 0 tot 100, waar 0 = 'n 
0% ofgeen kans en 100 = 'n 100% kans, bedoelende datjy dit heslis sal lay. Merk 
asseblief die horisontale Iyn om jou kans op dermkanker aan te duL Volgens jou 
opinie, waiter nommer van 0 tot 100 weerspicl!l jou kanse om dermkanker te lay? 
I I 
0% 10 20 30 40 50 60 70 80 90 100% 
Sebie F: Motiveering vir die ondemeeming in die voorspellings programme 
Kies asseblief die aantwword wat die heste pas 
62. My besluit om die voorspellings toets te neem is ••• 0 •••••••••••• 00 ••••• 0 
CI) 
Q) i'~ ·S ell 
] = Q) > !. ~ .;; .2 8 
0 ~ a::I Z_ 
Om oor my kinders se risiko te leer 
Om my risiko van dikderm kanker te verminder 
Om vir die toekoms te heplan 
Om navorsing te bevorder 
Om seker te wees oor my risiko 
Om 'n hesluit te kan neem oor gesinsbeplanning 
en te besluit of ek kinders wi) he of nie 
Huweliks hesluite 
Dokter het dit aanheveel 
My gesin het my gevra om die toets te neem 
Bekommered oor abnormale stoolgangl 
gesondheids kwale 












63. Probeer om te onthou hoe u gevoel het toe u 001' die toets moes besluit. Wat was uog 
vir u belangrik toe u besluit het om die toets te Deem ? 
64. Hoekom wou u Die die toets ueem uie? 
65. Is u tevrede met die besluit om die toets te ueem? (genetiese toets) 
66. Hoe betroubaar beskou u die toets? (genetiese toets) 
67. As jy weer moes besluit, sou jy weer vir die genetiese toets gaan, nou dat jy die 
resuitate weet? 
Seksie G: Gesondheids ooomg 
68. Na watter dag-hospitaal gaan u na toe wanneer u siek word? 
69. Is dit dieselfde hospital as die een waar jy gaan vir jou gesondheids kwessies vir 
dikderm Dnker? 
10. Het u mediesefonds? 
o Ja 
o Nee 
11. Het u al ooit 'n koionoskopie gehad? 
o Ja (Hoeveel?) 
o Nee 
o Ekweetnie 
12. Wanneer was u laute kolonoskopie? 
13. Wat Dn 'n kolonoskopie vir 'n mens vertel? 
14. Hoe venkil 'n kolonoskopie en 'n voonpelling5 toets van mekaar? 
15. Hoekom is altwee toetse nodig? 
76. Hoekom gaan u vir 'n kolonoskopie? 














78. Het u 'n kolonoskopie voor u genetiese toets gehad? 
o Ja 
o Nee 
Seksie H: Voonienbare emstigheidsgraad (ungeDD van Aktan-Collan 200n 
79. Indien u dikderm bnker ontwikkel, sou u dit oorleer! 
80. Is u bang dat u dalk bnker het? 
81. Hoe Iyk u toekoms? 
Seksie I: Opinie 001' berading 
82. Hoe behulpsaam beskou u die ondenteuningsdienslberadingsdiens? 




o Glad nie 
84. Het u al raadgewing ontvang na die toets resultate? 
o Ja 
o Nee 
8S. Het u enige verdere stellings ofvra? 
Die navorser bedank die deelnemer vir hulle onderneming in die onderhoud 
Die navorser sal die deelnemer veni-Ys vir genetiese berading indien ondersteuning en 












DIVISION OF HUMAN GENETICS 
Faculty of Health Sciences · University of Cape Town 
GENETIC TESTING 
Genetic testing is an examination of the DNA (basic material of hereditary) of an individual. 
Results of these tests may disprove or confirm a suspected fault or change (mutation) in the 
DNA. Genetic testing of DNA is performed on a blood sample collected from an individual. 
Predictive genetic testing is a means of knowing one's genetic status with regard to a 
particular condition. To undergo a predictive genetic test implies that one is forewarned 
about one's risk of developing a particular disorder before the signs and symptoms of that 
condition manifest it in an individual. 
HNPCC is a dominant inherited disorder with the result that all family members of an 
affected individual (first degree relative) are at 50% risk of developing cancer at an early 
age. Predictive genetic test for HNPCC is a relatively recent option available to individuals 
at risk for having inherited the gene for HNPCC. This test allows an individual a chance of 
knowing whether he I she has the mutation. Knowledge of one's genetic status, with regard 
to HNPCC, allows the individual to make informed decisions about commencing 
preventative screening for cancer. 
To take the test is a very serious decision. Therefore, it is important that subjects are well 
informed and understand the programme and procedures of predictive genetic testing that are 
necessary before finally getting the result. If after careful consideration. you decide to take 
the test, you will be requested to come to the Department of Human Genetics on at least 2 
occasions to see the geneticist involved in running the programme. Arrangements can be 
made to link you with the clinical team for screening if needed. 
PROGRAMME FOR PREDICTIVE TESTING - HNPCC 
1. Telephonic contact with family members re interest in predictive genetic testing. 












2. lst Meeting with genetieists: (Group session) Infonnation and implication of 
predictive genetic testing. 
The oukome of this meeting ean be: 
o You need time to assimilate what you have heard. The registered nurses will 
make contact with you within a week to discuss your decision. 
o You have opted to know your genetic status on HNPCC 
samples collected. with infonned consent. 
3. 2nd Meeting with genetieist: 
lst Blood 
o Those who have opted to know their genetic status during the 1 st meeting: 
meet individually with the geneticist and receive their genetic infonnation. 
They have the opportunity of asking further questions pertinent to their 
specific situation. A second blood sample will be collected for confinnatory 
analysis. Contact numbers of the support team will be given. Plan of action 
with regard to preventative screening will be discussed. Appointments 
(support team + screening) can be arranged. 
o Those who have decided to know their genetic status subsequent to the 1 st 
meeting: meet individually with geneticist to clear up any uncertainties. 
Meet with registered nurse to take 1 st blood specimen. 
4. 3rd Meeting with geneticist: 
o Those who have opted to know their genetic status during the 2nd meeting: 
meet individually with the geneticist and receive their genetic infonnation. 
They have the opportunity of asking further questions pertinent to their 
specific situation. A second blood sample will be collected for confinnatory 
analysis. Contact numbers of the support team will be given. Plan of action 
with regard to preventative screening will be discussed. Appointments 
(support team + screening) can be arranged. 
GENERAL INFORMATION ON THE HNPCC PREDICTIVE GENETIC 
TESTING PROGRAMME 
1. We strongly recommend that you infonn your family doctor of your decision to 











As part of the policy of this programme, we believe that the on-going medical care 
and support your doctor is able to give is very important to you and your family. A 
letter will be sent to your doctor (:with your permission) to inform himlher about the 
programme after the 2 I 3rd meeting. 
2. Support is essential and we therefore strongly advise that you choose a family 
member or a trusted friend to accompany you to all the meetings. (optional) 
3. The final results will be given to you approximately 1 month after your blood 
samples have been taken and will be strictly confidential. No results will be given to 
you by telephone. With your permission your family doctor will be contacted and 
written to regarding the results. 
4. If at any stage in the programme you decide you do not wish to continue, the 
decision is entirely yours. Your decision will in no way prejudice our relationship 
with you or your family. We will be happy to continue to offer you the support and 
help you need, within our capabilities. 
5. Reactions to predictive genetic testing might vary widely. Some people who might 
have the predisposing genetic defect may suffer a sense of shock and grief however 
well they may have been prepared beforehand. People whose test is negative may 
feel relief but at the same time suffer guilt and anxiety. A health care professional 
will be available to discuss any questions I problems you might encounter after 
entering into the HNPCC predictive genetic testing programme. 
6. No children under the age of 18 will be included in the HNPCC predictive genetic 
test programme. 
7. Those individuals who carry the mutation for HNPCC will be counselled with regard 
to best practice regarding regular colonoscopic and other relevant screenings for 
cancer - in private or provincial settings. 
8. Cost for the research leading to the finding of the genetic defect predisposing to 
colorectal cancer has been borne by the Division of Human Genetics. The 
(confirmation of diagnosis I predictive) laboratory test is available to members in 
families where the pre-genetic defect has been detected at an approximate cost of 
R596.40, which is generally payable through a medical aid scheme. Testing will not 
be denied to individuals who are unable to afford the cost. 
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